

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAPEZ1617

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/Caplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	29	JUN 25	CA/Caplus and USPAT databases updated with IPC reclassification data
NEWS	30	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	31	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated

organizations
NEWS 32 JUN 30 STN on the Web enhanced with new STN AnaVist
Assistant and BLAST plug-in
NEWS 33 JUN 30 STN AnaVist enhanced with database content from EPFULL
NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:03:47 ON 15 JUL 2008

=> file reg	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:04:00 ON 15 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUL 2008 HIGHEST RN 1034013-75-6
DICTIONARY FILE UPDATES: 14 JUL 2008 HIGHEST RN 1034013-75-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>


=>
Uploading C:\Program Files\STNEXP\Queries\10599488.str

L1 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS

L1

STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 exact sam

SAMPLE SEARCH INITIATED 10:04:45 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1 TO 80

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA EXA SAM L1

=> s l1 sss sam

SAMPLE SEARCH INITIATED 10:04:56 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 3 TO 163

PROJECTED ANSWERS: 0 TO 0

L3 0 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 10:05:06 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 23 TO ITERATE

100.0% PROCESSED 23 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.01

L4 6 SEA SSS FUL L1

=> file cap

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.82

179.03

FILE 'CAPLUS' ENTERED AT 10:05:11 ON 15 JUL 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Jul 2008 VOL 149 ISS 3

FILE LAST UPDATED: 14 Jul 2008 (20080714/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l4

L5 1 L4

=> d ibib abs hitstr

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1123882 CAPLUS

DOCUMENT NUMBER: 143:405796

TITLE: Preparation of aroyl-substituted pyrrolidines as histamine H3 receptor ligands

INVENTOR(S): Beavers, Lisa Selsam; Finley, Don Richard; Finn, Terry Patrick; Gadske, Robert Alan; Hipskind, Philip Arthur; Hornback, William Joseph; Jesudason, Cynthia Darshini; Pickard, Richard Todd; Takakuwa, Takako; Vaught, Grant Mathews

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 179 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097740	A1	20051020	WO 2005-US10240	20050325
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005230881	A1	20051020	AU 2005-230881	20050325
CA 2561628	A1	20051020	CA 2005-2561628	20050325
EP 1735278	A1	20061227	EP 2005-730691	20050325
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 1960969	A	20070509	CN 2005-80017146	20050325
BR 2005009298	A	20070918	BR 2005-9298	20050325
JP 2007530698	T	20071101	JP 2007-506412	20050325
MX 2006PA11167	A	20070125	MX 2006-PA11167	20060928
US 20070208024	A1	20070906	US 2006-599488	20060929
IN 2006KN02868	A	20070608	IN 2006-KN2868	20061005
PRIORITY APPLN. INFO.:			US 2004-558542P	P 20040401
			US 2004-617101P	P 20041008
			WO 2005-US10240	W 20050325
OTHER SOURCE(S):		CASREACT 143:405796; MARPAT 143:405796		
GI				



I



II


AB Title compds. I [Q, T, X, D = C, N provided no more than two are N; R1-3 = H, halo, alkyl, CN, carboxy, etc.; R4-5 = H, OH, halo, CF₂H, etc.; R6 = H, halo, CF₃, etc.] are prepared For instance, II is prepared in 3 steps from 4-(trifluoromethyl)phenylboronic acid, Me 4-bromobenzoate and (S)-1-(2-pyrrolidinylmethyl)pyrrolidine. Example compds. exhibit affinity for the H₃ receptor greater than 1 μ M. I have histamine-H₃ receptor antagonist or inverse agonist activity with affinity for the H₃ receptor greater than 1 μ M. I are useful for the treatment of obesity, cognitive deficiencies, narcolepsy, and other histamine H₃ receptor-related diseases.

IT 867255-05-8P 867255-06-9P 867255-15-0P
867256-21-1P 867256-22-2P 867256-31-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aroyl-substituted pyrrolidines as histamine H₃ receptor ligands)

RN 867255-05-8 CAPLUS

CN Methanone, [3-fluoro-4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl][(2S)-2-[(2R)-2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867255-06-9 CAPLUS

CN Methanone, [4'-(ethylsulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl][(2S)-2-[[2R)-2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867255-15-0 CAPLUS


CN Methanone, [3,5-difluoro-4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl] [(2S)-2-[(2R)-2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 867256-21-1 CAPLUS

CN Methanone, [3-fluoro-4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl] [2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867256-22-2 CAPLUS

CN Methanone, [4'-(ethylsulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl] [2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)



RN 867256-31-3 CAPLUS

CN Methanone, [3,5-difluoro-4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl][2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

7.37

186.40

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.80

-0.80

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 10:07:30 ON 15 JUL 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAPEZ1617

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	3	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	4	MAR 31	CA/Caplus and CASREACT patent number format for U.S. applications updated
NEWS	5	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	6	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	7	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	8	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	9	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	10	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	11	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	12	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	13	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	14	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	15	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	16	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	17	JUN 25	CA/Caplus and USPAT databases updated with IPC reclassification data
NEWS	18	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	19	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	20	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	21	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	22	JUL 28	CA/Caplus patent coverage enhanced
NEWS	23	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS	24	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	25	JUL 28	STN Viewer performance improved
NEWS	26	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:20:22 ON 07 AUG 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:20:31 ON 07 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 AUG 2008 HIGHEST RN 1039104-40-9
DICTIONARY FILE UPDATES: 6 AUG 2008 HIGHEST RN 1039104-40-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\10599488 base.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> s l1 sss full
 FULL SEARCH INITIATED 16:21:23 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 1861 TO ITERATE

100.0% PROCESSED 1861 ITERATIONS
 SEARCH TIME: 00.00.01

177 ANSWERS

L3 177 SEA SSS FUL L1

=> file cap
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 ENTRY SESSION
 FULL ESTIMATED COST 180.82 181.03

FILE 'CAPLUS' ENTERED AT 16:21:27 ON 07 AUG 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Aug 2008 VOL 149 ISS 6
 FILE LAST UPDATED: 6 Aug 2008 (20080806/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l3

L4 4 L3

=> d l4 1-4 ibib abs hitstr

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1237501 CAPLUS

DOCUMENT NUMBER: 147:502372

TITLE: Preparation of 2-benzyl-1,2,4-oxadiazolidinedione compounds as agonists of G protein-coupled receptor 40 (GPR40) and insulin-secretion enhancers

INVENTOR(S): Negoro, Kenji; Iwasaki, Fumiyoshi; Ohnuki, Kei; Kurosaki, Toshio; Yonetoku, Yasuhiro; Asai, Norio; Yoshida, Shigeru; Soga, Takatoshi

PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan

SOURCE: PCT Int. Appl., 202pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1




PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007123225	A1	20071101	WO 2007-JP58694	20070423
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: JP 2006-118630 A 20060424

OTHER SOURCE(S): MARPAT 147:502372

GI



AB The title compds. [I; R1 = H, halo, R0, halo-lower alkyl, ORz, SR0, halo-lower alkoxy; R0 = lower alkyl; Rz = H, lower alkyl; L = *-lower alkylene-O, *-lower alkylene-N(Rz)-, *-CON(Rz)- where * denotes the bonding to the ring A; the ring A = benzene, pyridine, thiophene, piperidine, dihydropyridine, pyrimidine, tetrahydroquinoline; the ring B = benzene, pyridine; R2 = halo, R0, halo-lower alkyl, ORz, SR0, halo-lower alkoxy, aryl-lower alkoxy, oxo; n = 0, 1, 2; R3 = halo, R0, halo-lower alkyl, OR0, SR0, halo-lower alkoxy, X-(un)substituted Ph, X-(un)substituted heteroaryl; X = a single bond, O, S, N(Rz); R4 = H, lower alkyl] or pharmacol. acceptable salts thereof are prepared. These compds. show an excellent insulin secretion enhancing effect and an excellent anti-hyperglycemic effect and useful as prophylactic/therapeutic agents for a disease associated with GPR40 such as diabetes. Thus, coupling of 2-[4-[(3-Bromobenzyl)oxy]benzyl]-1,2,4-oxadiazolidine-3,5-dione with 2,6-difluoro-4-methoxyphenylboronic acid in the presence of tetrakis(triphenylphosphine) palladium, LiCl, and NaHCO₃ in a mixture of H₂O, ethanol, and 1,2-diethoxyethane at 90° for 25 h followed by workup and silica gel chromatog. gave 2-[4-[(2',6'-difluoro-4'-methoxybiphenyl-3-yl)methoxy]benzyl]-3,5-dioxo-1,2,4-oxadiazolidine which was treated with 1 M aqueous NaOH solution in THF and ethanol to give 2-[4-[(2',6'-difluoro-4'-methoxybiphenyl-3-yl)methoxy]benzyl]-3,5-dioxo-1,2,4-oxadiazolidine sodium salt (II). II and 2-[4-[(4'-(2-hydroxyethoxy)biphenyl-3-yl)methoxy]benzyl]-1,2,4-oxadiazolidine-3,5-dione (III) showed EC₅₀ of 0.35 and 0.031 μM, resp., in a cellular calcium concentration assay using CHO cells expressing human GPR40.

IT 955927-98-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 2-benzyl-1,2,4-oxadiazolidinedione compds. as agonists of G protein-coupled receptor 40 (GPR40) and insulin-secretion enhancers for preventing or treating diabetes)

RN 955927-98-7 CAPLUS

CN 1,2,4-Oxadiazolidine-3,5-dione, 2-[[4-[(2'-methyl-4'-[(2R)-2-(1-pyrrolidinyl)methyl]-1-pyrrolidinyl]carbonyl][1,1'-biphenyl]-3-

yl]methoxy]phenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1123882 CAPLUS

DOCUMENT NUMBER: 143:405796

TITLE: Preparation of aroyl-substituted pyrrolidines as histamine H3 receptor ligands

INVENTOR(S): Beavers, Lisa Selsam; Finley, Don Richard; Finn, Terry Patrick; Galski, Robert Alan; Hipskind, Philip Arthur; Hornback, William Joseph; Jesudason, Cynthia Darshini; Pickard, Richard Todd; Takakuwa, Takako; Vaught, Grant Mathews

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 179 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097740	A1	20051020	WO 2005-US10240	20050325
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005230881	A1	20051020	AU 2005-230881	20050325
CA 2561628	A1	20051020	CA 2005-2561628	20050325
EP 1735278	A1	20061227	EP 2005-730691	20050325
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1960969	A	20070509	CN 2005-80017146	20050325
BR 2005009298	A	20070918	BR 2005-9298	20050325
JP 2007530698	T	20071101	JP 2007-506412	20050325
MX 2006PA11167	A	20070125	MX 2006-PA11167	20060928

US 20070208024
IN 2006KN02868
PRIORITY APPLN. INFO.:


A1 20070906
A 20070608

US 2006-599488 20060929
IN 2006-KN2868 20061005
US 2004-558542P P 20040401
US 2004-617101P P 20041008
WO 2005-US10240 W 20050325

OTHER SOURCE(S): CASREACT 143:405796; MARPAT 143:405796
GI



I



II

AB Title compds. I [Q, T, X, D = C, N provided no more than two are N; R1-3 = H, halo, alkyl, CN, carboxy, etc.; R4-5 = H, OH, halo, CF2H, etc.; R6 = H, halo, CF3, etc.] are prepared For instance, II is prepared in 3 steps from 4-(trifluoromethyl)phenylboronic acid, Me 4-bromobenzoate and (S)-1-(2-pyrrolidinylmethyl)pyrrolidine. Example compds. exhibit affinity for the H3 receptor greater than 1 μ M. I have histamine-H3 receptor antagonist or inverse agonist activity with affinity for the H3 receptor greater than 1 μ M. I are useful for the treatment of obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.


IT 867254-18-0P 867254-20-4P 867254-37-3P
867255-22-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of aroyl-substituted pyrrolidines as histamine H3 receptor ligands)

RN 867254-18-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(1,1-dimethylethyl)-4'-[[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-20-4 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(1,1-dimethylethyl)-N-methyl-4'--[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-37-3 CAPLUS

CN Methanone, (4'-nitro[1,1'-biphenyl]-4-yl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 867255-22-9 CAPLUS

CN [1,1'-Biphenyl]-4-sulfinic acid, 3'-fluoro-4'--[(2S)-2-[(2R)-2-methyl-1-

pyrrolidinyl)methyl]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 867253-91-6P 867253-92-7P 867253-93-8P
867253-94-9P 867253-96-1P 867253-98-3P
867254-00-0P 867254-02-2P 867254-04-4P
867254-05-5P 867254-06-6P 867254-11-3P
867254-13-5P 867254-14-6P 867254-17-9P
867254-19-1P 867254-21-5P 867254-23-7P
867254-24-8P 867254-25-9P 867254-26-0P
867254-27-1P 867254-28-2P 867254-29-3P
867254-30-6P 867254-34-0P 867254-35-1P
867254-36-2P 867254-38-4P 867254-39-5P
867254-40-8P 867254-41-9P 867254-42-0P
867254-43-1P 867254-44-2P 867254-46-4P
867254-47-5P 867254-48-6P 867254-50-0P
867254-53-3P 867254-59-9P 867254-61-3P
867254-65-7P 867254-67-9P 867254-71-5P
867254-72-6P 867254-78-2P 867254-81-7P
867254-82-8P 867254-83-9P 867254-84-0P
867254-85-1P 867254-86-2P 867254-87-3P
867254-88-4P 867254-89-5P 867254-90-8P
867254-91-9P 867254-92-0P 867254-93-1P
867254-94-2P 867254-95-3P 867254-96-4P
867254-98-6P 867255-03-6P 867255-05-8P
867255-06-9P 867255-07-0P 867255-08-1P
867255-09-2P 867255-10-5P 867255-11-6P
867255-12-7P 867255-13-8P 867255-14-9P
867255-15-0P 867255-20-7P 867255-21-8P
867255-26-3P 867255-33-2P 867255-34-3P
867255-35-4P 867255-36-5P 867255-38-7P
867255-39-8P 867255-40-1P 867255-41-2P
867255-42-3P 867255-43-4P 867255-44-5P
867255-47-8P 867255-49-0P 867255-50-3P
867255-53-6P 867255-54-7P 867255-55-8P
867255-56-9P 867255-57-0P 867255-59-2P
867255-60-5P 867255-61-6P 867255-62-7P
867255-63-8P 867255-64-9P 867255-65-0P
867255-66-1P 867255-70-7P 867255-71-8P
867255-72-9P 867255-73-0P 867255-74-1P
867255-75-2P 867255-76-3P 867255-77-4P
867255-78-5P 867255-79-6P 867255-80-9P
867255-81-0P 867255-82-1P 867255-83-2P
867255-84-3P 867255-86-5P 867255-89-8P

867255-90-1P 867255-92-3P 867255-94-5P
 867255-96-7P 867255-99-0P 867256-00-6P
 867256-01-7P 867256-02-8P 867256-03-9P
 867256-04-0P 867256-05-1P 867256-06-2P
 867256-07-3P 867256-08-4P 867256-09-5P
 867256-10-8P 867256-11-9P 867256-12-0P
 867256-13-1P 867256-14-2P 867256-15-3P
 867256-21-1P 867256-22-2P 867256-23-3P
 867256-24-4P 867256-25-5P 867256-27-7P
 867256-28-8P 867256-29-9P 867256-31-3P
 867256-36-8P 867256-37-9P 867256-38-0P
 867256-42-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of aroyl-substituted pyrrolidines as histamine H3 receptor
 ligands)

RN 867253-91-6 CAPLUS

CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4'-(
 (trifluoromethyl)[1,1'-biphenyl]-4-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 867253-92-7 CAPLUS

CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][2'-(
 (trifluoromethyl)[1,1'-biphenyl]-4-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 867253-93-8 CAPLUS

CN Methanone, (4'-chloro[1,1'-biphenyl]-4-yl)[(2S)-2-(1-pyrrolidinylmethyl)-1-
 pyrrolidinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 867253-94-9 CAPLUS

CN Methanone, (2'-chloro[1,1'-biphenyl]-4-yl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867253-96-1 CAPLUS

CN Methanone, [4'-(5-methyl-1,3,4-oxadiazol-2-yl)[1,1'-biphenyl]-4-yl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 867253-98-3 CAPLUS


CN Methanone, (3-fluoro[1,1'-biphenyl]-4-yl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 867253-97-2

CMF C22 H25 F N2 O

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 867254-00-0 CAPLUS


CN Methanone, (2',3-difluoro[1,1'-biphenyl]-4-yl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 867253-99-4

CMF C22 H24 F2 N2 O

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 867254-02-2 CAPLUS


CN Methanone, (2'-fluoro[1,1'-biphenyl]-4-yl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 867254-01-1

CMF C22 H25 F N2 O

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 867254-04-4 CAPLUS


CN Methanone, (4'-fluoro[1,1'-biphenyl]-4-yl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 867254-03-3

CMF C22 H25 F N2 O

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 867254-05-5 CAPLUS

CN Methanone, (3'-chloro[1,1'-biphenyl]-4-yl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-06-6 CAPLUS

CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-11-3 CAPLUS

CN Methanone, [3-chloro-4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-13-5 CAPLUS

CN Methanone, [4'-(cyclopropylcarbonyl)[1,1'-biphenyl]-4-yl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 867254-14-6 CAPLUS

CN [1,1'-Biphenyl]-4-carbonitrile, 4'--[(2S)-2-(1-pyrrolidinylmethyl)-1-

pyrrolidinyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-17-9 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N,N-dimethyl-4'--[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-19-1 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'--[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-21-5 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-methyl-4'--[[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-23-7 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-4'--[[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 867254-24-8 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N,N-dimethyl-4'--[[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 867254-25-9 CAPLUS

CN Methanone, [4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-26-0 CAPLUS

CN Pyrrolidine, 1-[[4'-(1-pyrrolidinylcarbonyl)[1,1'-biphenyl]-4-yl]carbonyl]-2-(1-pyrrolidinylmethyl)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-29-3 CAPLUS

CN Methanesulfonamide, N-[4'-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl][1,1'-biphenyl]-3-yl- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-30-6 CAPLUS

CN Methanone, [3'-(methanesulfonyl)[1,1'-biphenyl]-4-yl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-34-0 CAPLUS

CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4'-[(trifluoromethyl)sulfonyl][1,1'-biphenyl]-4-yl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 867254-35-1 CAPLUS

CN Methanesulfonamide, N-[3-fluoro-4'-[[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl][1,1'-biphenyl]-4-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-36-2 CAPLUS

CN Methanone, [4'-(ethylsulfonyl)[1,1'-biphenyl]-4-yl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-38-4 CAPLUS

CN Methanone, (4'-amino[1,1'-biphenyl]-4-yl) [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-39-5 CAPLUS

CN Methanone, (4'-methoxy[1,1'-biphenyl]-4-yl) [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-40-8 CAPLUS

CN Methanone, (4'-bromo[1,1'-biphenyl]-4-yl) [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-41-9 CAPLUS

CN Methanone, (2'-nitro[1,1'-biphenyl]-4-yl) [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-42-0 CAPLUS

CN Methanone, (4'-ethyl[1,1'-biphenyl]-4-yl) [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-43-1 CAPLUS

CN Methanone, [1,1'-biphenyl]-4-yl [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-44-2 CAPLUS

CN Methanone, (4'-propyl[1,1'-biphenyl]-4-yl) [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-46-4 CAPLUS

CN Methanone, [4'-(2-(1-piperidinyl)ethoxy)[1,1'-biphenyl]-4-yl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-47-5 CAPLUS

CN Methanone, [4'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-48-6 CAPLUS

CN Methanone, (4'-hexyl[1,1'-biphenyl]-4-yl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-50-0 CAPLUS

CN Pyrrolidine, 2-(1-pyrrolidinylmethyl)-1-([1,1':3',1''-terphenyl]-4-ylcarbonyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-53-3 CAPLUS

CN Methanone, [2-fluoro-4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-59-9 CAPLUS

CN Methanone, [4-(1,3-benzodioxol-5-yl)phenyl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-61-3 CAPLUS

CN Methanone, [4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-65-7 CAPLUS

CN Methanone, [(2S)-2-[[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl] [4'-(trifluoromethyl) [1,1'-biphenyl]-4-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-67-9 CAPLUS

CN Methanone, [(2S)-2-[(2S)-2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl][4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-71-5 CAPLUS

CN Methanone, [4'-(methylsulfonyl)-3-(trifluoromethyl)[1,1'-biphenyl]-4-yl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 867254-72-6 CAPLUS

CN Pyrrolidine, 1-[[4'-(methylsulfonyl)-3-(trifluoromethyl)[1,1'-biphenyl]-4-


yl]carbonyl]-2-(1-pyrrolidinylmethyl)-, (2S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 867254-71-5

CMF C24 H27 F3 N2 O3 S

Absolute stereochemistry.




CM 2

CRN 87-69-4

CMF C4 H6 O6


Absolute stereochemistry.



RN 867254-78-2 CAPLUS

CN Methanone, [3,5-difluoro-4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-81-7 CAPLUS

CN Methanesulfonamide, N-[3'-fluoro-4'-[[[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl][1,1'-biphenyl]-4-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-82-8 CAPLUS

CN Methanesulfonamide, N-[3'-fluoro-4'-[[[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl][1,1'-biphenyl]-4-yl]-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 867254-83-9 CAPLUS

CN Methanesulfonamide, N-[3'-fluoro-4'-[[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl][1,1'-biphenyl]-4-yl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-84-0 CAPLUS

CN Methanone, [3-fluoro-3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-85-1 CAPLUS

CN Methanone, [3-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-86-2 CAPLUS

CN [1,1'-Biphenyl]-3-carbonitrile, 3'-fluoro-4'-[[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-87-3 CAPLUS

CN Methanone, [3-fluoro-3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-88-4 CAPLUS

CN Methanone, [3-fluoro-4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-89-5 CAPLUS

CN Methanone, (3-fluoro-2',4'-dimethoxy[1,1'-biphenyl]-4-yl) [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-90-8 CAPLUS

CN Methanone, (3-fluoro-4'-methoxy[1,1'-biphenyl]-4-yl) [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-91-9 CAPLUS

CN Methanone, (3-fluoro-3',4'-dimethoxy[1,1'-biphenyl]-4-yl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-92-0 CAPLUS

CN Methanone, (3,4'-difluoro[1,1'-biphenyl]-4-yl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-93-1 CAPLUS

CN Methanone, [4-(1,3-benzodioxol-5-yl)-2-fluorophenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-94-2 CAPLUS

CN Methanone, [3-fluoro-3'-(1-pyrrolidinyl) [1,1'-biphenyl]-4-yl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-95-3 CAPLUS

CN Methanone, [3-fluoro-3'-(methylsulfonyl) [1,1'-biphenyl]-4-yl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-96-4 CAPLUS

CN Methanone, [4'-(ethylsulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867254-98-6 CAPLUS

CN Methanone, [3-fluoro-4'-(methylsulfinyl) [1,1'-biphenyl]-4-yl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867255-03-6 CAPLUS

CN Methanone, [2-fluoro-4-(1H-indol-5-yl)phenyl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 867255-05-8 CAPLUS

CN Methanone, [3-fluoro-4'-(methylsulfonyl) [1,1'-biphenyl]-4-yl] [(2S)-2-

[[(2R)-2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867255-06-9 CAPLUS

CN Methanone, [4'-(ethylsulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl][(2S)-2-[[(2R)-2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867255-07-0 CAPLUS

CN Methanone, [2-[[(2R,5R)-2,5-dimethyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl][4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 867255-08-1 CAPLUS

CN Methanone, [(2S)-2-[[(2R,5S)-2,5-dimethyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl][4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867255-09-2 CAPLUS


CN Methanone, [(2R)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 867255-10-5 CAPLUS
 CN Methanone, [(2S)-2-[[(2R)-2-ethyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl][4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 867255-11-6 CAPLUS
 CN Methanone, [(2S)-2-[[(2S)-2-(fluoromethyl)-1-pyrrolidinyl]methyl]-1-pyrrolidinyl][4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 867255-12-7 CAPLUS
 CN Methanone, [(2S)-2-[[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl][4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867255-13-8 CAPLUS

CN Methanone, [4'-(cyclopropylcarbonyl)-3-fluoro[1,1'-biphenyl]-4-yl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 867255-14-9 CAPLUS

CN Methanone, [4'-(cyclopropylcarbonyl)-3-fluoro[1,1'-biphenyl]-4-yl][(2S)-2-[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867255-15-0 CAPLUS

CN Methanone, [3,5-difluoro-4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl][(2S)-2-[[[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867255-20-7 CAPLUS

CN Methanone, [3-fluoro-4'-(methylthio)[1,1'-biphenyl]-4-yl][(2S)-2-[[[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867255-21-8 CAPLUS

CN Methanone, [3-fluoro-4'-(methylsulfinyl)[1,1'-biphenyl]-4-yl] [(2S)-2-
[(2R)-2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867255-26-3 CAPLUS


CN Methanone, [3,5-difluoro-4'-(methylsulfinyl)[1,1'-biphenyl]-4-yl] [(2S)-2-
(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 867255-33-2 CAPLUS

CN Methanone, [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl] [4'-(
trifluoromethyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 867255-34-3 CAPLUS

CN Methanone, [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 867255-35-4 CAPLUS

CN Methanone, (4'-chloro[1,1'-biphenyl]-4-yl)[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-36-5 CAPLUS

CN Methanone, (2'-chloro[1,1'-biphenyl]-4-yl) [2-(1-pyrrolidinymethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-38-7 CAPLUS

CN Methanone, [4'-(5-methyl-1,3,4-oxadiazol-2-yl) [1,1'-biphenyl]-4-yl] [2-(1-pyrrolidinymethyl)-1-pyrrolidinyl]- (CA INDEX NAME)



RN 867255-39-8 CAPLUS


CN Methanone, (3-fluoro[1,1'-biphenyl]-4-yl) [2-(1-pyrrolidinymethyl)-1-pyrrolidinyl]- (CA INDEX NAME)



RN 867255-40-1 CAPLUS


CN Methanone, (2',3-difluoro[1,1'-biphenyl]-4-yl) [2-(1-pyrrolidinymethyl)-1-pyrrolidinyl]-

pyrrolidinyl]- (CA INDEX NAME)




RN 867255-41-2 CAPLUS

CN Methanone, (2'-fluoro[1,1'-biphenyl]-4-yl) [2-(1-pyrrolidinymethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-42-3 CAPLUS

CN Methanone, (4'-fluoro[1,1'-biphenyl]-4-yl) [2-(1-pyrrolidinymethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-43-4 CAPLUS

CN Methanone, (3'-chloro[1,1'-biphenyl]-4-yl) [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-44-5 CAPLUS

CN Methanone, [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 867255-47-8 CAPLUS

CN Methanone, [3-chloro-4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl] [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-49-0 CAPLUS

CN Methanone, [4'-(cyclopropylcarbonyl)[1,1'-biphenyl]-4-yl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-50-3 CAPLUS

CN [1,1'-Biphenyl]-4-carbonitrile, 4'--[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)




RN 867255-53-6 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N,N-dimethyl-4'-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)




RN 867255-54-7 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(1,1-dimethylethyl)-4'-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)




RN 867255-55-8 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)




RN 867255-56-9 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(1,1-dimethylethyl)-N-methyl-4'-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)




RN 867255-57-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-methyl-4'-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)




RN 867255-59-2 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-4'-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)




RN 867255-60-5 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N,N-dimethyl-4'--[2-(1-pyrrolidinylmethyl)-1-pyrrolidinylcarbonyl]- (CA INDEX NAME)




RN 867255-61-6 CAPLUS

CN Methanone, [4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-62-7 CAPLUS

CN Pyrrolidine, 1-[[4'-(1-pyrrolidinylcarbonyl)[1,1'-biphenyl]-4-yl]carbonyl]-2-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 867255-63-8 CAPLUS

CN Methanone, [3-fluoro-4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-64-9 CAPLUS

CN Methanesulfonamide, N-[4'-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl][1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 867255-65-0 CAPLUS

CN Methanesulfonamide, N-[4'-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 867255-66-1 CAPLUS

CN Methanone, [3'-(methanesulfonyl)[1,1'-biphenyl]-4-yl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-70-7 CAPLUS

CN Methanone, [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4'-(trifluoromethyl)sulfonyl][1,1'-biphenyl]-4-yl- (CA INDEX NAME)




RN 867255-71-8 CAPLUS

CN Methanesulfonamide, N-[3-fluoro-4'-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl][1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 867255-72-9 CAPLUS

CN Methanone, [4'-(ethylsulfonyl)[1,1'-biphenyl]-4-yl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-73-0 CAPLUS

CN Methanone, (4'-nitro[1,1'-biphenyl]-4-yl)[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-74-1 CAPLUS

CN Methanone, (4'-amino[1,1'-biphenyl]-4-yl)[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-75-2 CAPLUS

CN Methanone, (4'-methoxy[1,1'-biphenyl]-4-yl)[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-76-3 CAPLUS

CN Methanone, (4'-bromo[1,1'-biphenyl]-4-yl) [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-77-4 CAPLUS

CN Methanone, (2'-nitro[1,1'-biphenyl]-4-yl) [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-78-5 CAPLUS

CN Methanone, (4'-ethyl[1,1'-biphenyl]-4-yl)[2-(1-pyrrolidinymethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-79-6 CAPLUS

CN Methanone, [1,1'-biphenyl]-4-yl[2-(1-pyrrolidinymethyl)-1-pyrrolidinyl]- (CA INDEX NAME)



RN 867255-80-9 CAPLUS


CN Methanone, (4'-propyl[1,1'-biphenyl]-4-yl)[2-(1-pyrrolidinymethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-81-0 CAPLUS

CN Methanone, [4'-[2-(1-piperidinyl)ethoxy][1,1'-biphenyl]-4-yl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 867255-82-1 CAPLUS


CN Methanone, [4'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl][2-(1-

pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-83-2 CAPLUS

CN Methanone, (4'-hexyl[1,1'-biphenyl]-4-yl)[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-84-3 CAPLUS

CN Pyrrolidine, 2-(1-pyrrolidinylmethyl)-1-([1,1':3',1''-terphenyl]-4-ylcarbonyl)- (9CI) (CA INDEX NAME)




RN 867255-86-5 CAPLUS

CN Methanone, [2-fluoro-4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl][2-(1-pyrrolidinymethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-89-8 CAPLUS

CN Methanone, [4-(1,3-benzodioxol-5-yl)phenyl][2-(1-pyrrolidinymethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-90-1 CAPLUS

CN Methanone, [4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl][2-(1-pyrrolidinymethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-92-3 CAPLUS

CN Methanone, [2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl][4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 867255-94-5 CAPLUS

CN Methanone, [4'-(methylsulfonyl)-3-(trifluoromethyl)[1,1'-biphenyl]-4-yl][2-(1-pyrrolidinymethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-96-7 CAPLUS

CN Methanone, [3,5-difluoro-4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867255-99-0 CAPLUS

CN Methanesulfonamide, N-[3'-fluoro-4'-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl][1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 867256-00-6 CAPLUS

CN Methanesulfonamide, N-[3'-fluoro-4'-[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl][1,1'-biphenyl]-4-yl]-N-methyl- (CA INDEX NAME)




RN 867256-01-7 CAPLUS

CN Methanone, [3-fluoro-3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867256-02-8 CAPLUS

CN Methanone, [3-fluoro-4'-(trifluoromethyl) [1,1'-biphenyl]-4-yl] [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867256-03-9 CAPLUS

CN [1,1'-Biphenyl]-3-carbonitrile, 3'-fluoro-4'-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)




RN 867256-04-0 CAPLUS

CN Methanone, [3-fluoro-3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867256-05-1 CAPLUS

CN Methanone, [3-fluoro-4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867256-06-2 CAPLUS

CN Methanone, (3-fluoro-2',4'-dimethoxy[1,1'-biphenyl]-4-yl)[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867256-07-3 CAPLUS

CN Methanone, (3-fluoro-4'-methoxy[1,1'-biphenyl]-4-yl) [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867256-08-4 CAPLUS

CN Methanone, (3-fluoro-3',4'-dimethoxy[1,1'-biphenyl]-4-yl) [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867256-09-5 CAPLUS

CN Methanone, (3,4'-difluoro[1,1'-biphenyl]-4-yl) [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)



RN 867256-10-8 CAPLUS


CN Methanone, [4-(1,3-benzodioxol-5-yl)-2-fluorophenyl] [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)



RN 867256-11-9 CAPLUS


CN Methanone, [4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-fluorophenyl] [2-(1-

pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867256-12-0 CAPLUS

CN Methanone, [3-fluoro-3'-(1-pyrrolidinyl)[1,1'-biphenyl]-4-yl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867256-13-1 CAPLUS

CN Methanone, [3-fluoro-3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867256-14-2 CAPLUS

CN Methanone, [4'-(ethylsulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867256-15-3 CAPLUS

CN Methanone, [3-fluoro-4'-(methylsulfinyl)[1,1'-biphenyl]-4-yl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867256-21-1 CAPLUS

CN Methanone, [3-fluoro-4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl][2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867256-22-2 CAPLUS

Methanone, [4'-(ethylsulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl][2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867256-23-3 CAPLUS

CN Methanone, [2-[(2,5-dimethyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl][4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 867256-24-4 CAPLUS

CN Methanone, [2-[(2-ethyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl][4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 867256-25-5 CAPLUS

CN Methanone, [2-[[2-(fluoromethyl)-1-pyrrolidinyl]methyl]-1-pyrrolidinyl][4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 867256-27-7 CAPLUS

CN Methanone, [2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl][4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 867256-28-8 CAPLUS

CN Methanone, [4'-(cyclopropylcarbonyl)-3-fluoro[1,1'-biphenyl]-4-yl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867256-29-9 CAPLUS

CN Methanone, [4'-((cyclopropylcarbonyl)-3-fluoro[1,1'-biphenyl]-4-yl)]2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl- (CA INDEX NAME)




RN 867256-31-3 CAPLUS

CN Methanone, [3,5-difluoro-4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl)]2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl- (CA INDEX NAME)




RN 867256-36-8 CAPLUS

CN Methanone, [3-fluoro-4'-(methylthio)[1,1'-biphenyl]-4-yl][2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867256-37-9 CAPLUS

CN Methanone, [3-fluoro-4'-(methylsulfinyl)[1,1'-biphenyl]-4-yl][2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)




RN 867256-38-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfinic acid, 3'-fluoro-4'--[[2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)




RN 867256-42-6 CAPLUS

CN Methanone, [3,5-difluoro-4'-(methylsulfinyl)[1,1'-biphenyl]-4-yl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)



IT 867256-59-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of aroyl-substituted pyrrolidines as histamine H3 receptor
 ligands)
 RN 867256-59-5 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-4'-[[[(2S)-2-(1-pyrrolidinylmethyl)-
 1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on SIN
 ACCESSION NUMBER: 2004:41436 CAPLUS
 DOCUMENT NUMBER: 140:93917
 TITLE: Preparation of pyrrolidine derivatives as oxytocin
 antagonists
 INVENTOR(S): Jorand-Lebrun, Catherine; Dorbaix, Jerome;
 Quattropani, Anna; Schwarz, Matthias; Valognes,
 Delphine
 PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N.V., Neth.
 Antilles


SOURCE: PCT Int. Appl., 73 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004005249	A1	20040115	WO 2003-EP50286	20030704
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2487532	A1	20040115	CA 2003-2487532	20030704
AU 2003254498	A1	20040123	AU 2003-254498	20030704
BR 2003012586	A	20050412	BR 2003-12586	20030704
EP 1532109	A1	20050525	EP 2003-762692	20030704
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1678576	A	20051005	CN 2003-820401	20030704
JP 2005533828	T	20051110	JP 2004-518783	20030704
MX 2005PA00326	A	20050331	MX 2005-PA326	20050105
NO 2005000612	A	20050203	NO 2005-612	20050203
US 20060004020	A1	20060105	US 2005-518543	20050711
US 7115754	B2	20061003		
HK 1076107	A1	20071207	HK 2005-110274	20051117
PRIORITY APPLN. INFO.:			EP 2002-100784	A 20020705
			WO 2003-EP50286	W 20030704
OTHER SOURCE(S):		MARPAT 140:93917		
GI				



- AB The title compds. I [R1 = H or alkyl; R2 = H, alkyl, (substituted)aryl, (substituted)heteroaryl, etc.; R3 = aryl or heteroaryl; X = O or (substituted)amino; n = 1-3] were prepared as oxytocin antagonists for the prevention and/or treatment of preterm labor, premature birth or dysmenorrhea. Thus, reaction of 1-tert-butyl-2-Me (2S)-4-(methoxyimino)-1,2-pyrrolidine-dicarboxylate (preparation given) with 2'-methyl[1,1'-biphenyl]-4-carboxylic acid followed by hydrolysis and reduction gave compound II. The latter inhibits oxytocin mediated Ca²⁺-mobilization with IC₅₀ = 0.03 μM. Pharmaceutical compns. containing I are described.
- IT 643001-63-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyrrolidine derivs. as oxytocin antagonists)
- RN 643001-63-2 CAPLUS
- CN 1H-Indole-1,3(2H)-dione, 2-[[[(2S)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:784071 CAPLUS

DOCUMENT NUMBER: 140:12454

TITLE: Design and synthesis of pyrrolidine-5,5'-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 4. Antiviral activity and plasma stability

AUTHOR(S): Borthwick, Alan D.; Davies, Dave E.; Ertl, Peter F.; Exall, Anne M.; Haley, Terry M.; Hart, Graham J.; Jackson, Deborah L.; Parry, Nigel R.; Patikis, Angela; Trivedi, Naimisha; Weingarten, Gordon G.; Woolven, James M.

CORPORATE SOURCE: Department of Medicinal Chemistry CVU UK, Medicines Research Centre, GlaxoSmithKline Research and Development, Herts, SG1 2NY, UK

SOURCE: Journal of Medicinal Chemistry (2003), 46(21), 4428-4449

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:12454

AB A series of chiral, (S)-proline- α -methylpyrrolidine-5,5'-trans-lactam serine protease inhibitors has been developed as antivirals of human cytomegalovirus (HCMV). The SAR of the functionality on the proline nitrogen has shown that derivs. of para-substituted Ph ureas > para-substituted Ph sulfonamides > para-substituted Ph carboxamide for activity against HCMV δ Ala protease, producing para-substituted Ph ureas with single figure nM potency (K_i) against the viral enzyme. The SAR of the functionality on the lactam nitrogen has defined the steric and electronic requirements for high human plasma stability while retaining good activity against HCMV protease. The combination of high potency against HCMV δ Ala protease and high human plasma stability has produced compds. with significant in vitro antiviral activity against human cytomegalovirus with the 6-hydroxymethyl benzothiazole derivative 72 being equivalent in potency to ganciclovir. The parent benzothiazole 56 had good pharmacokinetics in dogs with 29% bioavailability and good brain and ocular penetration in guinea pigs.


IT 628725-63-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis and antiviral structure activity relationships of pyrrolidine-lactams as inhibitors of human cytomegalovirus protease)

RN 628725-63-3 CAPLUS
 CN Pyrrolo[3,2-b]pyrrol-2(1H)-one, 4-[[(2S)-1-([1,1'-biphenyl]-4-ylcarbonyl)-
 2-pyrrolidinyl]carbonyl]-1-(cyclopropylcarbonyl)hexahydro-3-methyl-,
 (3S,3aR,6aS)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file stng

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	24.68	205.71
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.20	-3.20

FILE 'STNGUIDE' ENTERED AT 16:24:49 ON 07 AUG 2008
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Aug 1, 2008 (20080801/UP).

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF		
LOGOFF? (Y)/N/HOLD:y		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	205.77
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.20

STN INTERNATIONAL LOGOFF AT 16:25:09 ON 07 AUG 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAPEZ1617

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	3	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	4	MAR 31	CA/Caplus and CASREACT patent number format for U.S. applications updated
NEWS	5	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	6	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	7	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	8	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	9	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	10	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	11	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	12	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	13	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	14	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	15	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	16	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	17	JUN 25	CA/Caplus and USPAT databases updated with IPC reclassification data
NEWS	18	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	19	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	20	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	21	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	22	JUL 28	CA/Caplus patent coverage enhanced
NEWS	23	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS	24	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	25	JUL 28	STN Viewer performance improved
NEWS	26	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:48:07 ON 07 AUG 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:48:16 ON 07 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 AUG 2008 HIGHEST RN 1039104-40-9
DICTIONARY FILE UPDATES: 6 AUG 2008 HIGHEST RN 1039104-40-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\10599488 base 1.str

L1 STRUCTURE UPLOADED

=>
Uploading C:\Program Files\STNEXP\Queries\10599488 base 2.str

L2 STRUCTURE UPLOADED


=>
Uploading C:\Program Files\STNEXP\Queries\10599488 base 3.str

L3 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS

L1

STR




Structure attributes must be viewed using STN Express query preparation.

=> d 12

L2 HAS NO ANSWERS

L2 STR




Structure attributes must be viewed using STN Express query preparation.

=> d 13

L3 HAS NO ANSWERS

L3 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 16:49:58 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 862 TO ITERATE

100.0% PROCESSED 862 ITERATIONS 0 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 15479 TO 19001
 PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 16:50:04 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 17917 TO ITERATE

100.0% PROCESSED 17917 ITERATIONS 0 ANSWERS
 SEARCH TIME: 00.00.01

L5 0 SEA SSS FUL L1

=> s l2 sss full

FULL SEARCH INITIATED 16:50:14 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 204 TO ITERATE

100.0% PROCESSED 204 ITERATIONS 1 ANSWERS
 SEARCH TIME: 00.00.01

L6 1 SEA SSS FUL L2

=> s l3 sss full


FULL SEARCH INITIATED 16:50:20 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 17917 TO ITERATE

100.0% PROCESSED 17917 ITERATIONS 0 ANSWERS
 SEARCH TIME: 00.00.05

L7 0 SEA SSS FUL L3

=> d 16

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 653588-61-5 REGISTRY
ED Entered STN: 24 Feb 2004
CN Acetic acid, 2-[[4'-(1-piperidinylcarbonyl)[1,1'-biphenyl]-4-yl]sulfonyl]-
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Acetic acid, [[4'-(1-piperidinylcarbonyl)[1,1'-biphenyl]-4-yl]sulfonyl]-
(9CI)
MF C20 H21 N O5 S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file cap

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	537.54	537.75

FILE 'CAPLUS' ENTERED AT 16:50:40 ON 07 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Aug 2008 VOL 149 ISS 6
FILE LAST UPDATED: 6 Aug 2008 (20080806/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 16

L8 1 L6

=> d ibib abs hitstr

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:958402 CAPLUS

DOCUMENT NUMBER: 140:138737

TITLE: Discovery of Small-Molecule Inhibitors of the ATPase Activity of Human Papillomavirus E1 Helicase
AUTHOR(S): Faucher, Anne-Marie; White, Peter W.; Brochu, Christian; Grand-Maitre, Chantal; Rancourt, Jean; Fazal, Gulrez

CORPORATE SOURCE: Research and Development, Boehringer Ingelheim (Canada) Ltd., Laval, QC, H7S 2G5, Can.

SOURCE: Journal of Medicinal Chemistry (2004), 47(1), 18-21
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal


LANGUAGE: English

AB The Boehringer Ingelheim compound collection was screened for inhibitors of the ATPase activity of human papillomavirus E1 helicase to develop antiviral agents that inhibit human papillomavirus (HPV) DNA replication. This screen led to the discovery of (biphenyl-4-sulfonyl)acetic acid 1, which inhibits the ATPase activity of HPV type 6 E1 helicase with a low micromolar IC50 value. A hit-to-lead exercise rapidly converted 1 into a low nanomolar lead series.

IT 653588-61-5
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(discovery of small-mol. inhibitors of ATPase activity of human Papillomavirus E1 helicase)

RN 653588-61-5 CAPLUS

CN Acetic acid, 2-[[4'-(1-piperidinylcarbonyl)[1,1'-biphenyl]-4-yl]sulfonyl]-
(CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
6.89	544.64

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.80	-0.80

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 16:52:32 ON 07 AUG 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAPEZ1617

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	3	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	4	MAR 31	CA/Caplus and CASREACT patent number format for U.S. applications updated
NEWS	5	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	6	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	7	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	8	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	9	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	10	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	11	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	12	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	13	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	14	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	15	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	16	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	17	JUN 25	CA/Caplus and USPAT databases updated with IPC reclassification data
NEWS	18	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	19	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	20	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	21	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	22	JUL 28	CA/Caplus patent coverage enhanced
NEWS	23	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS	24	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	25	JUL 28	STN Viewer performance improved
NEWS	26	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:22:22 ON 07 AUG 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:22:47 ON 07 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 AUG 2008 HIGHEST RN 1039104-40-9
DICTIONARY FILE UPDATES: 6 AUG 2008 HIGHEST RN 1039104-40-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\10599488 base 4.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 17:23:13 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3364 TO ITERATE

59.5% PROCESSED 2000 ITERATIONS

18 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 63802 TO 70758

PROJECTED ANSWERS: 275 TO 935

L2 18 SEA SSS SAM L1

=> d scan


L2 18 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN Methanone, [4-[4-(methylthio)butoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-

MF C21 H32 N2 O2 S

CI COM

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 18 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN Methanone, [4-[(4-fluorophenyl)methoxy]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-

MF C23 H27 F N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 18 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN Methanone, [5-chloro-2,4-bis(methoxymethoxy)phenyl][(2R)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-

MF C20 H29 Cl N2 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 sss ful

FULL SEARCH INITIATED 17:23:40 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 66839 TO ITERATE

100.0% PROCESSED 66839 ITERATIONS

574 ANSWERS

SEARCH TIME: 00.00.01

L3 574 SEA SSS FUL L1

=> file cap

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.82

179.03

FILE 'CAPLUS' ENTERED AT 17:23:45 ON 07 AUG 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Aug 2008 VOL 149 ISS 6

FILE LAST UPDATED: 6 Aug 2008 (20080806/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 13
L4 45 L3

=> s 14 and obesity
51744 OBESITY
85 OBESITIES
51747 OBESITY
(OBESITY OR OBESITIES)

L5 13 L4 AND OBESITY

=> s 15 and histamine
62152 HISTAMINE
271 HISTAMINES
62215 HISTAMINE
(HISTAMINE OR HISTAMINES)

L6 8 L5 AND HISTAMINE

=> d 16 1-6 ibib abs hitstr

L6 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2008 ACS on SIN

ACCESSION NUMBER: 2007:31382 CAPLUS

DOCUMENT NUMBER: 146:142501

TITLE: Preparation of pyrrolidine derivatives as
histamine H3 antagonists or inverse agonists

INVENTOR(S): Beavers, Lisa Selsam; Finley, Don Richard; Gadske,
Robert Alan; Hipskind, Philip Arthur; Hornback,
William Joseph; Jesudason, Cynthia Darshini; Pickard,
Richard Todd; Takakuwa, Takako; Vaught, Grant Mathews

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 65pp.
CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007005503	A1	20070111	WO 2006-US25328	20060628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006265997	A1	20070111	AU 2006-265997	20060628
CA 2613192	A1	20070111	CA 2006-2613192	20060628
EP 1904442	A1	20080402	EP 2006-774260	20060628
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
MX 200716216	A	20080311	MX 2007-16216	20071217
IN 2007KN04926	A	20080328	IN 2007-KN4926	20071219
PRIORITY APPLN. INFO.:			US 2005-696257P	P 20050701
			WO 2006-US25328	W 20060628
OTHER SOURCE(S):		MARPAT 146:142501		
GI				



I


- AB The title compds. I [R1 = -N-pyrrolidinyl (wherein the pyrrolidine is optionally substituted with R4), -N-morpholinyl, etc.; R4 = Me, CF₃, CN, etc.; R6 = H, (un)substituted alkyl; R7 = H, (un)substituted alkyl] are prepared I are useful for the treatment of histamine H₃ receptor-related diseases. Thus, [4-(2-pyrrolidin-1-ylethylamino)phenyl]-(2-(S)-pyrrolidin-1-ylmethylpyrrolidin-1-yl)methanone was prepared in 2 steps from (S)-(+)-1-(2-pyrrolidinylmethyl)pyrrolidine and 4-fluorobenzoyl chloride. In an assay for inhibition of [35S]GTPy[S] binding to H₃R membranes in the presence of agonists, one compound of this invention showed the K_i value of 11.7 nM.
- IT 919113-29-4P 919113-52-3P 919113-53-4P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyrrolidine derivs. as histamine H₃ antagonists or inverse agonists)
- RN 919113-29-4 CAPLUS
- CN Methanone, [4-[2-(cyclopentylamino)ethyl]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




- RN 919113-52-3 CAPLUS
- CN Benzenemethanesulfonamide, N-[4-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 919113-53-4 CAPLUS
 CN Benzenesulfonamide, 4-(methylsulfonyl)-N-[4-[[2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 919113-13-6P 919113-15-8P 919113-17-0P
 919113-19-2P 919113-23-8P 919113-25-0P
 919113-27-2P 919113-31-8P 919113-33-0P
 919113-35-2P 919113-37-4P 919113-39-6P
 919113-41-0P 919113-43-2P 919113-45-4P
 919113-47-6P 919113-49-8P 919113-50-1P
 919113-51-2P 919113-54-5P 919113-55-6P
 919113-56-7P 919113-57-8P 919113-58-9P
 919113-59-0P 919113-60-3P 919113-61-4P
 919113-62-5P 919113-63-6P 919113-64-7P
 919113-66-9P 919113-68-1P 919113-70-5P
 919113-71-6P 919113-72-7P 919113-73-8P
 919113-74-9P 919113-75-0P 919113-76-1P
 919113-77-2P 919113-78-3P 919113-79-4P
 919113-80-7P 919113-81-8P 919113-82-9P
 919113-83-0P 919113-84-1P 919113-85-2P
 919113-86-3P 919113-87-4P 919113-88-5P
 919113-89-6P 919113-90-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolidine derivs. as histamine H3 antagonists or inverse agonists)

RN 919113-13-6 CAPLUS
 CN Methanone, [4-[2-(1-pyrrolidinyl)ethylamino]phenyl][2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 919113-15-8 CAPLUS

CN Methanone, [4-[[3-(1-piperidinyl)propylamino]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 919113-17-0 CAPLUS

CN Methanone, [4-(butylamino)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 919113-19-2 CAPLUS


CN Methanone, [4-(diethylamino)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 919113-23-8 CAPLUS
 CN Urea, N-butyl-N'-[4-[[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenyl]-, pentamer (CA INDEX NAME)

Absolute stereochemistry.




RN 919113-25-0 CAPLUS
 CN Benzenesulfonamide, N,N-dipropyl-4-[[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 919113-27-2 CAPLUS
 CN Methanone, [4-(dimethylamino)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 919113-31-8 CAPLUS

CN Methanone, [4-[2-(cyclopentylamino)ethyl]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 919113-33-0 CAPLUS

CN Methanone, [4-[2-[(phenylmethyl)amino]ethyl]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, pentamer (CA INDEX NAME)


Absolute stereochemistry.



RN 919113-35-2 CAPLUS

CN Methanone, [4-[2-(1-piperidinyl)ethyl]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 919113-37-4 CAPLUS

CN Methanone, [4-[2-(1-pyrrolidinyl)ethyl]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 919113-39-6 CAPLUS

CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-[3-(1-pyrrolidinyl)propyl]phenyl]-, pentamer (CA INDEX NAME)


Absolute stereochemistry.



RN 919113-41-0 CAPLUS

CN Methanone, [4-[2-(4-methyl-1-piperazinyl)ethyl]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 919113-43-2 CAPLUS

CN Methanone, [4-[2-(diethylamino)ethyl]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 919113-45-4 CAPLUS

CN Benzamide, N-[3-(1-piperidinyl)propyl]-4-[[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]-, pentamer (CA INDEX NAME)


Absolute stereochemistry.



RN 919113-47-6 CAPLUS


CN Methanone, [4-(1-piperidylsulfonyl)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, pentamer (CA INDEX NAME)

Absolute stereochemistry.




RN 919113-49-8 CAPLUS
 CN Methanone, [4-(4-morpholinylsulfonyl)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 919113-50-1 CAPLUS
 CN Methanone, [4-[[3-(methylsulfonyl)-1-pyrrolidinyl]sulfonyl]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 919113-51-2 CAPLUS
 CN Benzenemethanesulfonamide, N-[4-[[[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 919113-54-5 CAPLUS

CN Benzenesulfonamide, N-methyl-4-(methylsulfonyl)-N-[4-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 919113-55-6 CAPLUS

CN Methanone, [4-[[3-(4-pyridinyl)propyl]thio]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 919113-56-7 CAPLUS
 CN Methanone, [4-[[3-(3-pyridinyl)propyl]thio]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 919113-57-8 CAPLUS
 CN Methanone, [4-(4-pyridinylthio)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 919113-58-9 CAPLUS

CN Benzamide, N-[2-(3-pyridinyl)ethyl]-4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 919113-59-0 CAPLUS

CN Methanone, [4-(4-pyrimidinylthio)phenyl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 919113-60-3 CAPLUS

CN Methanone, [4-(3-pyridinylthio)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl


RN 919113-61-4 CAPLUS

CN Methanone, [4-[[2-(1-pyrrolidinyl)ethyl]amino]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 919113-62-5 CAPLUS

CN Methanone, [4-[[3-(1-piperidinyl)propyl]amino]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 919113-63-6 CAPLUS

CN Methanone, [4-(butylamino)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)




RN 919113-64-7 CAPLUS

CN Methanone, [4-(diethylamino)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 919113-66-9 CAPLUS

CN Urea, N-butyl-N'-[4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenyl]- (CA INDEX NAME)




RN 919113-68-1 CAPLUS

CN Benzenesulfonamide, N,N-dipropyl-4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)




RN 919113-70-5 CAPLUS

CN Methanone, [4-(dimethylamino)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 919113-71-6 CAPLUS

CN Methanone, [4-[2-(cyclopentylamino)ethyl]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 919113-72-7 CAPLUS

CN Methanone, [4-[2-[(phenylmethyl)amino]ethyl]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 919113-73-8 CAPLUS

CN Methanone, [4-[2-(1-piperidinyl)ethyl]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 919113-74-9 CAPLUS

CN Methanone, [4-[2-(1-pyrrolidinyl)ethyl]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 919113-75-0 CAPLUS

CN Methanone, [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-[3-(1-pyrrolidinyl)propyl]phenyl]- (CA INDEX NAME)




RN 919113-76-1 CAPLUS

CN Methanone, [4-[2-(4-methyl-1-piperazinyl)ethyl]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 919113-77-2 CAPLUS

CN Methanone, [4-[2-(diethylamino)ethyl]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 919113-78-3 CAPLUS

CN Benzanide, N-[3-(1-piperidinyl)propyl]-4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)




RN 919113-79-4 CAPLUS

CN Methanone, [4-(1-piperidinylsulfonyl)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 919113-80-7 CAPLUS

CN Methanone, [4-(4-morpholinylsulfonyl)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 919113-81-8 CAPLUS

CN Methanone, [4-[3-(methylsulfonyl)-1-pyrrolidinyl]sulfonyl]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 919113-82-9 CAPLUS

CN Benzenemethanesulfonamide, N-[4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenyl]- (CA INDEX NAME)




RN 919113-83-0 CAPLUS

CN Benzenesulfonamide, 4-(methylsulfonyl)-N-[4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenyl]- (CA INDEX NAME)




RN 919113-84-1 CAPLUS

CN Benzenesulfonamide, N-methyl-4-(methylsulfonyl)-N-[4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenyl]- (CA INDEX NAME)




RN 919113-85-2 CAPLUS

CN Methanone, [4-[[3-(4-pyridinyl)propyl]thio]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 919113-86-3 CAPLUS

CN Methanone, [4-[[3-(3-pyridinyl)propyl]thio]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)



RN 919113-87-4 CAPLUS


CN Methanone, [4-(4-pyridinylthio)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 919113-88-5 CAPLUS

CN Benzanide, N-[2-(3-pyridinyl)ethyl]-4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 919113-89-6 CAPLUS

CN Methanone, [4-(4-pyrimidinylthio)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 919113-90-9 CAPLUS

CN Methanone, [4-(3-pyridinylthio)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




IT 867256-58-4P 911697-02-4P 911697-03-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of pyrrolidine derivs. as histamine H3 antagonists or
 inverse agonists)
 RN 867256-58-4 CAPLUS
 CN Methanone, (4-bromophenyl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
 (CA INDEX NAME)

Absolute stereochemistry.




RN 911697-02-4 CAPLUS
 CN Methanone, [4-(2-chloroethyl)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911697-03-5 CAPLUS
 CN Methanone, (4-fluorophenyl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
 (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1065918 CAPLUS

DOCUMENT NUMBER: 145:418937

TITLE: Preparation of phenyl pyrrolidinylmethylpyrrolidinyl methanones as histamine H3 receptor agents.

INVENTOR(S): Hipskind, Philip Arthur; Takakuwa, Takako; Jesudason, Cynthia Darshini; Gadske, Robert Alan; Hornback, William Joseph; Pickard, Richard Todd; Beavers, Lisa Selsam

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 66pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006107661	A1	20061012	WO 2006-US11320	20060328
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006232871	A1	20061012	AU 2006-232871	20060328
CA 2602234	A1	20061012	CA 2006-2602234	20060328
EP 1868991	A1	20071226	EP 2006-758217	20060328
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
IN 2007KN03101	A	20071228	IN 2007-KN3101	20070823
MX 200712110	A	20071121	MX 2007-12110	20070928
CN 101151244	A	20080326	CN 2006-80010841	20070929
PRIORITY APPLN. INFO.:			US 2005-667582P	P 20050401

OTHER SOURCE(S):

MARPAT 145:418937

GI



I

AB Title compds. [I; X, Y = C, N; ≥ 1 of X, Y = C; R¹ = halo, cyano, NO₂, (halo)alkyl, cycloalkyl, alkylsulfonylalkyl, cycloalkylcarbonyl, cycloalkylthio, alkenyl, alkynyl, (substituted) phenylcarbonylalkyl, etc.; R⁴, R⁵ = H, halo, (halo)alkyl, OR³; R⁶ = H, halo, CF₃, (halo)alkyl, OR³; R³ = H, (halo)alkyl], were prepared. Thus, (4-benzenesulfonylphenyl)[2-(S)-pyrrolidin-1-ylmethylpyrrolidin-1-yl]methanone (preparation outlined) showed K_i = 12 nM in a [35S] GTP γ [S] binding assay.

IT 867256-58-4P 867256-60-8P 867256-66-4P
 867256-68-6P 867256-69-7P 867256-75-5P
 867256-76-6P 867256-81-3P 877675-35-9P
 911696-48-5P 911696-50-9P 911696-52-1P
 911696-54-3P 911696-56-5P 911696-58-7P
 911696-60-1P 911696-62-3P 911696-63-4P
 911696-64-5P 911696-65-6P 911696-66-7P
 911696-68-9P 911696-69-0P 911696-70-3P
 911696-71-4P 911696-72-5P 911696-73-6P
 911696-74-7P 911696-75-8P 911696-76-9P
 911696-77-0P 911696-78-1P 911696-79-2P
 911696-80-5P 911696-81-6P 911696-83-8P
 911696-85-0P 911696-86-1P 911696-87-2P
 911696-88-3P 911696-89-4P 911696-90-7P
 911696-91-8P 911696-92-9P 911696-93-0P
 911696-94-1P 911696-95-2P 911696-96-3P
 911696-97-4P 911696-98-5P 911697-00-2P
 911697-01-3P 911697-02-4P 911697-03-5P
 911697-04-6P 911697-05-7P 911697-06-8P
 911697-07-9P 911697-08-0P 911697-10-4P
 911697-12-6P 911842-17-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(claimed compound; preparation of Ph pyrrolidinylmethylpyrrolidinyl methanones

as histamine H₃ receptor agents)

RN 867256-58-4 CAPLUS

CN Methanone, (4-bromophenyl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867256-60-8 CAPLUS

CN Methanone, (4-bromo-2-fluorophenyl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867256-66-4 CAPLUS

CN Methanone, (4-bromo-3-fluorophenyl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867256-68-6 CAPLUS

CN Methanone, [4-bromo-2-(trifluoromethyl)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867256-69-7 CAPLUS

CN Methanone, (4-bromo-2,6-difluorophenyl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867256-75-5 CAPLUS

CN Methanone, (4-bromo-2,6-difluorophenyl)[(2S)-2-[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867256-76-6 CAPLUS

CN Methanone, (4-bromo-2-fluorophenyl)[(2S)-2-[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 867256-81-3 CAPLUS


CN Methanone, (4-bromophenyl)[(2S)-2-[[[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 877675-35-9 CAPLUS

CN Methanone, (4-bromophenyl)[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 911696-48-5 CAPLUS

CN Methanone, (4-pentylphenyl)[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 911696-50-9 CAPLUS

CN Methanone, [4-(methylthio)phenyl] [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)




RN 911696-52-1 CAPLUS

CN Methanone, [4-[(4-methylcyclohexyl)thio]phenyl] [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)




RN 911696-54-3 CAPLUS

CN Methanone, [4-(methylsulfonyl)phenyl] [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)




RN 911696-56-5 CAPLUS

CN Methanone, (4-methylphenyl) [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA
INDEX NAME)




RN 911696-58-7 CAPLUS

CN Methanone, (4-ethylphenyl) [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA
INDEX NAME)




RN 911696-60-1 CAPLUS

CN Methanone, (4-propylphenyl) [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA
INDEX NAME)




RN 911696-62-3 CAPLUS

CN Methanone, (4-butylphenyl) [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 911696-63-4 CAPLUS

CN Methanone, [4-(phenylmethyl)phenyl] [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 911696-64-5 CAPLUS

CN Methanone, (3,4-dimethylphenyl) [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 911696-65-6 CAPLUS

CN Methanone, [4-(1,1-dimethylethyl)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 911696-66-7 CAPLUS

CN Pyrrolidine, 1-(4-benzoylbenzoyl)-2-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 911696-68-9 CAPLUS

CN Pyrrolidine, 1-[4-(3-oxo-3-phenylpropyl)benzoyl]-2-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 911696-69-0 CAPLUS

CN Methanone, [4-(5-phenylpentyl)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 911696-70-3 CAPLUS

CN Methanone, [4-(2-chloroethyl)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 911696-71-4 CAPLUS

CN Methanone, (4-bromo-2-fluorophenyl)[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 911696-72-5 CAPLUS

CN Methanone, (4-fluorophenyl) [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 911696-73-6 CAPLUS

CN Methanone, (4-bromo-2-fluorophenyl) [2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)




RN 911696-74-7 CAPLUS


CN Methanone, [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl] [4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 911696-75-8 CAPLUS
 CN Methanone, (4-chlorophenyl) [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA
 INDEX NAME)



RN 911696-76-9 CAPLUS
 CN Benzonitrile, 4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]- (CA
 INDEX NAME)




RN 911696-77-0 CAPLUS
 CN Methanone, (4-nitrophenyl) [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA
 INDEX NAME)




RN 911696-78-1 CAPLUS

CN Methanone, [4-bromo-2-(trifluoromethyl)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 911696-79-2 CAPLUS

CN Methanone, (4-bromo-2,6-difluorophenyl)[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 911696-80-5 CAPLUS

CN Ethanone, 1-[4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenyl]- (CA INDEX NAME)




RN 911696-81-6 CAPLUS

CN Methanone, [4-(cyclopropylcarbonyl)phenyl] [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 911696-83-8 CAPLUS

CN Methanone, [4-(phenylsulfonyl)phenyl] [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 911696-85-0 CAPLUS

CN Methanone, (4-bromo-3-fluorophenyl) [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 911696-86-1 CAPLUS

CN Methanone, (4-bromophenyl) [2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)



RN 911696-87-2 CAPLUS


CN Methanone, (4-bromo-2,6-difluorophenyl) [2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)



RN 911696-88-3 CAPLUS

CN Methanone, (4-pentylphenyl) [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 911696-89-4 CAPLUS

CN Methanone, [4-(methylthio)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 911696-90-7 CAPLUS

CN Methanone, [4-(methylsulfonyl)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 911696-91-8 CAPLUS

CN Methanone, (4-methylphenyl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 911696-92-9 CAPLUS

CN Methanone, (4-ethylphenyl) [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 911696-93-0 CAPLUS

CN Methanone, (4-propylphenyl) [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 911696-94-1 CAPLUS

CN Methanone, (4-butylphenyl) [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 911696-95-2 CAPLUS

CN Methanone, [4-(phenylmethyl)phenyl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 911696-96-3 CAPLUS

CN Methanone, (3,4-dimethylphenyl) [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 911696-97-4 CAPLUS


CN Methanone, [4-(1,1-dimethylethyl)phenyl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 911696-98-5 CAPLUS
 CN Pyrrolidine, 1-(4-benzoylbenzoyl)-2-(1-pyrrolidinylmethyl)-, (2S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 911697-00-2 CAPLUS
 CN Pyrrolidine, 1-[4-(3-oxo-3-phenylpropyl)benzoyl]-2-(1-pyrrolidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911697-01-3 CAPLUS
 CN Methanone, [4-(5-phenylpentyl)phenyl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 911697-02-4 CAPLUS

CN Methanone, [4-(2-chloroethyl)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 911697-03-5 CAPLUS

CN Methanone, [4-(2-chloroethyl)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 911697-04-6 CAPLUS

CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 911697-05-7 CAPLUS

CN Methanone, (4-chlorophenyl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 911697-06-8 CAPLUS

CN Benzonitrile, 4-[[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 911697-07-9 CAPLUS


CN Methanone, (4-nitrophenyl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 911697-08-0 CAPLUS
 CN Ethanone, 1-[4-[(2*S*)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 911697-10-4 CAPLUS
 CN Methanone, [4-(cyclopropylcarbonyl)phenyl][(2*S*)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 911697-12-6 CAPLUS
 CN Methanone, [4-(phenylsulfonyl)phenyl][(2*S*)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911842-17-6 CAPLUS
CN Methanone, [4-[(4-methylcyclohexyl)thio]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1011326 CAPLUS

DOCUMENT NUMBER: 145:377194

TITLE: Preparation of (1-benzoylpyrrolidin-2-yl)(pyrrolidino)methanes and related derivatives as histamine H3 receptor antagonists

INVENTOR(S): Beavers, Lisa Selsam; Finley, Don Richard; Galski, Robert Alan; Hipskind, Philip Arthur; Jesudason, Cynthia Darshini; Pickard, Richard Todd; Stevens, Freddie Craig; Takakuwa, Takako

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 92pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006101808	A1	20060928	WO 2006-US8943	20060313
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,			

MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM


AU 2006227815	A1	20060928	AU 2006-227815	20060313
CA 2600757	A1	20060928	CA 2006-2600757	20060313
EP 1861360	A1	20071205	EP 2006-738050	20060313

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR


MX 200711374	A	20071123	MX 2007-11374	20070914
CN 101142180	A	20080312	CN 2006-80008595	20070917
IN 2007KN03514	A	20080321	IN 2007-KN3514	20070919

PRIORITY APPLN. INFO.: US 2005-662686P P 20050317
WO 2006-US8943 W 20060313

OTHER SOURCE(S): MARPAT 145:377194
GI



I



II

AB The invention is related to the preparation of title compds. I [Y = C or N; R1 = H, cyclo/alkenyl, (un)substituted cyclo/alkyl, Ph; R4, R5 = independently H, halo, OH, etc.; R6 = independently at each occurrence H, halo, CF3OH, etc.; with provisos] and their pharmaceutically acceptable salts which are histamine H3 receptor antagonists or inverse agonists. The invention is also related to pharmaceutical compns. comprising pyrrolidines I as well as to the use of compns. I for treating obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. Thus, coupling 4-hydroxybenzoic acid with (S)-(+)-1-[(2-Pyrrolidinyl)methyl]pyrrolidine gave pyrrolidine II in 52% yield. (R)-(4-Butoxyphenyl)[2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl]methanone bound to human H3 receptors, expressing a Ki value of 145 nM in a GTPy[S] binding assay.


IT 464900-48-9P 871489-49-5P 910643-82-2P,
[S]-[4-(3-Phenylpropoxy)phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl]methanone

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of benzoylpyrrolidine derivs. as histamine H3 receptor antagonists and inverse agonists)

RN 464900-48-9 CAPLUS

CN Methanone, (3-fluoro-4-hydroxyphenyl) [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871489-49-5 CAPLUS

CN Methanone, (4-hydroxyphenyl) [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 910643-82-2 CAPLUS

CN Methanone, [4-(3-phenylpropoxy)phenyl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 464900-35-4P, (S)-[4-(3-Chloropropoxy)phenyl] [2-[(pyrrolidin-1-

yl)methyl]pyrrolidin-1-yl)methanone 871489-50-8P,
(S)-(2-Fluoro-4-hydroxyphenyl)[2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone 871489-59-7P 910643-38-8P,
(S)-(4-Butoxy-3-fluorophenyl)[2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone 910643-39-9P, (S)-(4-Propoxyphenyl)[2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone 910643-40-2P,
(S)-(4-Butoxyphenyl)[2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone 910643-41-3P, (S)-[4-(2-Chloroethoxy)phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone 910643-42-4P,
(S)-[4-[(5-Chloropentyl)oxy]phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone 910643-43-5P, (R)-(4-Butoxyphenyl)[2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone 910643-44-6P,
(S)-[2-[(Pyrrrolidin-1-yl)methyl]pyrrolidin-1-yl][4-(1,1,2,2-tetrafluoroethoxy)phenyl)methanone 910643-45-7P,
(S)-[4-(2-Hydroxyethoxy)phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone 910643-46-8P, (S)-[4-(3-Fluoropropoxy)phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone hydrochloride 910643-48-0P, (S)-[4-(3-Methoxypropoxy)phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone trifluoroacetate 910643-49-1P,
(S)-[4-(3-Methylsulfonylpropoxy)phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone 910643-50-4P,
(S)-[4-(3-Hydroxypropoxy)phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone 910643-51-5P, (+)-(S)-4-[4-[[2-[(Pyrrrolidin-1-yl)methyl]pyrrolidin-1-yl]carbonyl]phenoxy]butanoic acid methyl ester 910643-52-6P, (+)-(S)-5-[4-[[2-[(Pyrrrolidin-1-yl)methyl]pyrrolidin-1-yl]carbonyl]phenoxy]pentanoic acid methyl ester 910643-53-7P,
(+)-(S)-5-[4-[[2-[(Pyrrrolidin-1-yl)methyl]pyrrolidin-1-yl]carbonyl]phenoxy]pentanoic acid lithium salt 910643-56-0P,
(S)-[2-[(Pyrrrolidin-1-yl)methyl]pyrrolidin-1-yl][4-(4,4,4-trifluorobutoxy)phenyl)methanone 910643-57-1P,
(S)-[4-[[5-Fluoropentyl]oxy]phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone 910643-59-3P, (S)-[4-(4-Fluorobutoxy)phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone trifluoroacetate 910643-61-7P, (S)-[4-(2-Phenylsulfonylethoxy)phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone trifluoroacetate 910643-63-9P, (S)-[4-(4-Methylsulfonylbutoxy)phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone trifluoroacetate 910643-65-1P, (S)-[2-[(Pyrrrolidin-1-yl)methyl]pyrrolidin-1-yl][4-(3,3,3-trifluoropropoxy)phenyl)methanone trifluoroacetate 910643-66-2P, (S)-(4-Pentyloxyphenyl)[2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone 910643-68-4P,
(S)-(4-Isobutoxyphenyl)[2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone 910643-69-5P, (S)-(4-Isopropoxyphenyl)[2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone 910643-70-8P,
(S)-[4-(Cyclohexylmethoxy)phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone 910643-71-9P, (S)-(4-Heptyloxyphenyl)[2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone 910643-72-0P,
(S)-[4-(Difluoromethoxy)phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone 910643-73-1P, (S)-(4-Ethoxyphenyl)[2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone 910643-74-2P,
(S)-(4-Hexyloxyphenyl)[2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone 910643-75-3P, (S)-[2-[(Pyrrrolidin-1-yl)methyl]pyrrolidin-1-yl][4-(trifluoromethoxyphenyl)methanone 910643-76-4P, (S)-[4-(2-Butoxyethoxy)phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone 910643-77-5P,
(S)-[4-(2-Phenoxyethoxy)phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone 910643-78-6P, (S)-[4-(Cyclopentylloxy)phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone 910643-79-7P 910643-80-0P, (S)-[4-[(But-3-enyl)oxy]phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone 910643-81-1P 910643-83-3P, (S)-[4-(3-Phenylpropoxy)phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl)methanone hydrochloride 910643-84-4P,


(S)-[4-Phenoxyphenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl]methanone
 910643-86-6P, (S)-[4-(4-Phenoxybutoxy)phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl]methanone trifluoroacetate 910643-88-8P
 , (S)-[4-(3-Phenoxypropoxy)phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl]methanone trifluoroacetate 910643-90-2P, (S)-[4-[3-(4-Methoxyphenyl)propoxy]phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl]methanone trifluoroacetate 910643-91-3P, (S)-[4-(3-Methylsulfonylphenoxy)phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl]methanone hydrochloride 910643-92-4P,
 (S)-[4-(4-Methylsulfonylphenoxy)phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl]methanone hydrochloride 910643-95-7P
 910643-96-8P 910643-97-9P 910643-98-0P
 910643-99-1P 910644-00-7P 910644-01-8P
 910644-03-0P 910644-04-1P 910644-05-2P
 910644-06-3P 910644-07-4P 910644-08-5P
 910644-09-6P 910644-10-9P 910644-13-2P
 910644-14-3P 910644-15-4P 910644-16-5P
 910644-17-6P 910644-18-7P 910644-19-8P
 910644-20-1P 910644-21-2P 910644-22-3P
 910644-23-4P 910644-24-5P 910644-25-6P
 910644-26-7P 910644-27-8P 910644-28-9P
 910644-29-0P 910644-30-3P 910644-31-4P
 910644-32-5P 910644-33-6P 910644-34-7P
 910644-35-8P 910644-36-9P 910644-37-0P
 910644-38-1P 910644-39-2P 910644-40-5P
 910644-41-6P 910644-42-7P 910644-43-8P
 910644-44-9P 910644-47-2P 910644-48-3P,
 (R)-[4-(3-Chloropropoxy)phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl]methanone
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzoylpyrrolidine derivs. as histamine H3 receptor antagonists and inverse agonists)

RN 464900-35-4 CAPLUS

CN Methanone, [4-(3-chloropropoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871489-50-8 CAPLUS

CN Methanone, (2-fluoro-4-hydroxyphenyl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871489-59-7 CAPLUS

CN Methanone, (2-fluoro-4-hydroxyphenyl)[(2S)-2-[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 910643-38-8 CAPLUS

CN Methanone, (4-butoxy-3-fluorophenyl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 910643-39-9 CAPLUS

CN Methanone, (4-propoxyphenyl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 910643-40-2 CAPLUS

CN Methanone, (4-butoxyphenyl) [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 910643-41-3 CAPLUS

CN Methanone, [4-(2-chloroethoxy)phenyl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 910643-42-4 CAPLUS

CN Methanone, [4-[(5-chloropentyl)oxy]phenyl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 910643-43-5 CAPLUS

CN Methanone, (4-butoxyphenyl)-[(2R)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 910643-44-6 CAPLUS

CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 910643-45-7 CAPLUS

CN Methanone, [4-(2-hydroxyethoxy)phenyl]-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 910643-46-8 CAPLUS

CN Methanone, [4-(3-fluoropropoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 910643-48-0 CAPLUS


CN Methanone, [4-(3-methoxypropoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 910643-47-9

CMF C20 H30 N2 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 910643-49-1 CAPLUS

CN Methanone, [4-[3-(methylsulfonyl)propoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 910643-50-4 CAPLUS

CN Methanone, [4-(3-hydroxypropoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 910643-51-5 CAPLUS

CN Butanoic acid, 4-[4-[[[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 910643-52-6 CAPLUS

CN Pentanoic acid, 5-[4-[[[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 910643-53-7 CAPLUS

CN Pentanoic acid, 5-[4-[[[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]-, lithium salt (1:1) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● Li

RN 910643-56-0 CAPLUS


CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-(4,4,4-trifluorobutoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 910643-57-1 CAPLUS
 CN Methanone, [4-[(5-fluoropentyl)oxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 910643-59-3 CAPLUS
 CN Methanone, [4-(4-fluorobutoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 910643-58-2
 CMF C20 H29 F N2 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 910643-61-7 CAPLUS
 CN Methanone, [4-[2-(phenylsulfonyl)ethoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 910643-60-6

CMF C24 H30 N2 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 910643-63-9 CAPLUS
 CN Methanone, [4-[4-(methylthio)butoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 910643-62-8

CMF C21 H32 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 910643-65-1 CAPLUS


CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-(3,3,3-trifluoropropoxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 910643-64-0

CMF C19 H25 F3 N2 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 910643-66-2 CAPLUS

CN Methanone, [4-(pentyloxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 910643-68-4 CAPLUS

CN Methanone, [4-(2-methylpropoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 910643-69-5 CAPLUS


CN Methanone, [4-(1-methylethoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 910643-70-8 CAPLUS
 CN Methanone, [4-(cyclohexylmethoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 910643-71-9 CAPLUS
 CN Methanone, [4-(heptyloxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 910643-72-0 CAPLUS
 CN Methanone, [4-(difluoromethoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 910643-73-1 CAPLUS
 CN Methanone, (4-ethoxyphenyl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 910643-74-2 CAPLUS

CN Methanone, [4-(hexyloxy)phenyl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 910643-75-3 CAPLUS

CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 910643-76-4 CAPLUS

CN Methanone, [4-(2-butoxyethoxy)phenyl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 910643-77-5 CAPLUS

CN Methanone, [4-(2-phenoxyethoxy)phenyl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 910643-78-6 CAPLUS

CN Methanone, [4-(cyclopentyloxy)phenyl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 910643-79-7 CAPLUS

CN Methanone, [4-(3-methylbutoxy)phenyl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 910643-80-0 CAPLUS

CN Methanone, [4-(3-buten-1-yloxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 910643-81-1 CAPLUS

CN Methanone, [4-(2-cyclohexen-1-yloxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 910643-83-3 CAPLUS

CN Methanone, [4-(3-phenylpropoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 910643-84-4 CAPLUS

CN Methanone, (4-phenoxyphenyl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 910643-86-6 CAPLUS


CN Methanone, [4-(4-phenoxybutoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 910643-85-5

CMF C26 H34 N2 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 910643-88-8 CAPLUS


CN Methanone, [4-(3-phenoxypropoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 910643-87-7

CMF C25 H32 N2 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 910643-90-2 CAPLUS


CN Methanone, [4-[3-(4-methoxyphenyl)propoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 910643-89-9

CMF C26 H34 N2 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 910643-91-3 CAPLUS

CN Methanone, [4-[3-(methylsulfonyl)phenoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 910643-92-4 CAPLUS

CN Methanone, [4-[4-(methylsulfonyl)phenoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 910643-95-7 CAPLUS

CN Methanone, (4-hydroxyphenyl)-[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)




RN 910643-96-8 CAPLUS

CN Methanone, (4-butoxy-3-fluorophenyl)-[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)




RN 910643-97-9 CAPLUS

CN Methanone, (4-propoxyphenyl)-[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)




RN 910643-98-0 CAPLUS

CN Methanone, (4-butoxyphenyl) [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910643-99-1 CAPLUS

CN Methanone, [4-(2-chloroethoxy)phenyl] [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-00-7 CAPLUS

CN Methanone, [4-[(5-chloropentyl)oxy]phenyl] [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-01-8 CAPLUS

CN Methanone, [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (CA INDEX NAME)




RN 910644-03-0 CAPLUS

CN Methanone, [4-(2-hydroxyethoxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-04-1 CAPLUS

CN Methanone, [4-(3-fluoropropoxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-05-2 CAPLUS

CN Methanone, [4-(3-methoxypropoxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-06-3 CAPLUS

CN Methanone, [4-[3-(methylsulfonyl)propoxy]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-07-4 CAPLUS

CN Methanone, [4-(3-hydroxypropoxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-08-5 CAPLUS

CN Butanoic acid, 4-[[4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]-, methyl ester (CA INDEX NAME)




RN 910644-09-6 CAPLUS

CN Pentanoic acid, 5-[4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]-, methyl ester (CA INDEX NAME)



RN 910644-10-9 CAPLUS


CN Pentanoic acid, 5-[4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]-, lithium salt (1:1) (CA INDEX NAME)



● Li


RN 910644-13-2 CAPLUS

Methanone, [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-(4,4,4-trifluorobutoxy)phenyl]- (CA INDEX NAME)




RN 910644-14-3 CAPLUS

CN Methanone, [4-[(5-fluoropentyl)oxy]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-15-4 CAPLUS

CN Methanone, [4-(4-fluorobutoxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-16-5 CAPLUS

CN Methanone, [4-[2-(phenylsulfonyl)ethoxy]phenyl] [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-17-6 CAPLUS

CN Methanone, [4-[4-(methylthio)butoxy]phenyl] [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-18-7 CAPLUS

CN Methanone, [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl] [4-(3,3,3-trifluoropropoxy)phenyl]- (CA INDEX NAME)




RN 910644-19-8 CAPLUS

CN Methanone, (2-fluoro-4-hydroxyphenyl) [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-20-1 CAPLUS

CN Methanone, (2-fluoro-4-hydroxyphenyl) [2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-21-2 CAPLUS

CN Methanone, [4-(pentyloxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)




RN 910644-22-3 CAPLUS

CN Methanone, (4-methoxyphenyl) [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)




RN 910644-23-4 CAPLUS

CN Methanone, [4-(2-methylpropoxy)phenyl] [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-24-5 CAPLUS

CN Methanone, [4-(1-methylethoxy)phenyl] [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-25-6 CAPLUS

CN Methanone, [4-(cyclohexylmethoxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-26-7 CAPLUS

CN Methanone, [4-(heptyloxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-27-8 CAPLUS

CN Methanone, [4-(difluoromethoxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-28-9 CAPLUS

CN Methanone, (4-ethoxyphenyl) [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-29-0 CAPLUS

CN Methanone, [4-(hexyloxy)phenyl] [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-30-3 CAPLUS

CN Methanone, [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl] [4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 910644-31-4 CAPLUS

CN Methanone, [4-(2-butoxyethoxy)phenyl] [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-32-5 CAPLUS

CN Methanone, [4-(2-phenoxyethoxy)phenyl] [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-33-6 CAPLUS

CN Methanone, [4-(cyclopentyloxy)phenyl] [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-34-7 CAPLUS

CN Methanone, [4-(3-methylbutoxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-35-8 CAPLUS

CN Methanone, [4-(3-buten-1-yloxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-36-9 CAPLUS

CN Methanone, [4-(2-cyclohexen-1-yloxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-37-0 CAPLUS

CN Methanone, [4-(3-phenylpropoxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)



RN 910644-38-1 CAPLUS


CN Methanone, [4-(3-phenylpropoxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 910644-39-2 CAPLUS

CN Methanone, (4-phenoxyphenyl) [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)




RN 910644-40-5 CAPLUS

CN Methanone, [4-(4-phenoxybutoxy)phenyl] [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-41-6 CAPLUS

CN Methanone, [4-(3-phenoxypropoxy)phenyl] [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-42-7 CAPLUS

CN Methanone, [4-[3-(4-methoxyphenyl)propoxy]phenyl] [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 910644-43-8 CAPLUS

CN Methanone, [4-[3-(methylsulfonyl)phenoxy]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)



RN 910644-44-9 CAPLUS


CN Methanone, [4-[4-(methylsulfonyl)phenoxy]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)



RN 910644-47-2 CAPLUS

CN Methanone, (4-methoxyphenyl) [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 910644-48-3 CAPLUS

CN Methanone, [4-(3-chloropropoxy)phenyl] [(2R)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)

Absolute stereochemistry.



IT 867256-58-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(intermediate; preparation of benzoylpyrrolidine derivs. as
histamine H3 receptor antagonists and inverse agonists)

RN 867256-58-4 CAPLUS

CN Methanone, (4-bromophenyl) [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on SIN

ACCESSION NUMBER: 2006:383322 CAPLUS

DOCUMENT NUMBER: 144:432686

TITLE: Benzoylpyrrolidines as histamine H3 receptor
inhibitors, their preparation, pharmaceutical
compositions, and use in therapy

INVENTOR(S): Jesudason, Cynthia Darshini; Stevens, Freddie Craig

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006044228	A1	20060427	WO 2005-US36023	20051011
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1805169	A1	20070711	EP 2005-804419	20051011
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
JP 2008516952	T	20080522	JP 2007-536740	20051011
US 20080015235	A1	20080117	US 2007-577388	20070417
PRIORITY APPLN. INFO.:			US 2004-619785P	P 20041018
			WO 2005-US36023	W 20051011
OTHER SOURCE(S):		CASREACT 144:432686; MARPAT 144:432686		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to benzoylpyrrolidines I, which are histamine H3 receptor antagonists or inverse agonists. In compds. I, R1 is (un)substituted 5-membered heteroaryl ring containing 1-4 heteroatoms independently selected from N, O, and S; R4 and R5 are independently selected from H, OH, halo, optionally halo-substituted C1-3 alkyl, and optionally halo-substituted C1-3 alkoxy; and each R6 is independently selected from H, halo, OH, NH2, optionally halo-substituted C1-3 alkyl, (optionally halo-substituted C1-7 alkyl)n-amino, and optionally halo-substituted C1-7 alkoxy, where n is 1 or 2. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I and a pharmaceutically acceptable carrier, as well as to the use of the compns. to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. Coupling of N-Boc-proline with (R)-2-methylpyrrolidine hydrochloride followed by deprotection and hydride reduction gave chiral pyrrolidine II, which was coupled with 2-fluoro-4-hydroxybenzoic acid to give compound III. Substitution of 3-(chloromethyl)-1,2,4-oxadiazole with III gave benzoylpyrrolidine IV. Compound IV has high affinity for human H3 receptors, expressing a Ki value of 1.8 nM.

IT 884658-56-4P 884658-57-5P 884658-59-7P
 884658-61-1P 884658-62-2P 884658-63-3P
 884658-64-4P 884658-65-5P 884658-66-6P
 884658-67-7P 884658-68-8P 884658-69-9P
 884658-70-2P 884658-71-3P 884658-72-4P
 884658-73-5P 884658-74-6P 884658-75-7P
 884658-76-8P 884658-77-9P 884658-78-0P
 884658-79-1P 884658-80-4P 884658-81-5P,
 5-[[4-(2-Pyrrolidin-1-ylmethylpyrrolidine-1-carbonyl)phenoxy]methyl]thiophene-2-carbonitrile 884658-82-6P, [2-Fluoro-4-(thiazol-4-ylmethoxy)phenyl](2-pyrrolidin-1-ylmethylpyrrolidin-1-yl)methanone 884658-83-7P, [4-(Furan-2-ylmethoxy)phenyl](2-pyrrolidin-1-ylmethylpyrrolidin-1-yl)methanone 884658-84-8P,
 5-[[3-Fluoro-4-(2-pyrrolidin-1-ylmethylpyrrolidine-1-carbonyl)phenoxy]methyl]thiophene-2-carbonitrile 884658-85-9P,
 [2,6-Difluoro-4-(thiazol-4-ylmethoxy)phenyl](2-pyrrolidin-1-ylmethylpyrrolidin-1-yl)methanone 884658-86-0P,
 [2-Fluoro-4-(thiazol-4-ylmethoxy)phenyl][2-(2-methylpyrrolidin-1-ylmethyl)pyrrolidin-1-yl]methanone 884658-87-1P,
 [2,6-Difluoro-4-(thiazol-4-ylmethoxy)phenyl][2-(2-methylpyrrolidin-1-ylmethyl)pyrrolidin-1-yl]methanone 884658-88-2P,
 [2-Fluoro-4-(2-methylthiazol-4-ylmethoxy)phenyl](2-pyrrolidin-1-ylmethylpyrrolidin-1-yl)methanone 884658-89-3P,
 [2-Fluoro-4-(thiophen-3-ylmethoxy)phenyl](2-pyrrolidin-1-ylmethylpyrrolidin-1-yl)methanone 884658-90-6P,
 [2-Fluoro-4-(thiophen-3-ylmethoxy)phenyl][2-(2-methylpyrrolidin-1-ylmethyl)pyrrolidin-1-yl]methanone 884658-91-7P,
 [2-Fluoro-4-(thiophen-2-ylmethoxy)phenyl](2-pyrrolidin-1-ylmethylpyrrolidin-1-yl)methanone 884658-92-8P,
 [2-Fluoro-4-(thiophen-2-ylmethoxy)phenyl][2-(2-methylpyrrolidin-1-ylmethyl)pyrrolidin-1-yl]methanone 884658-93-9P,
 5-[[3-Fluoro-4-[2-(2-methylpyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl]phenoxy]methyl]thiophene-2-carbonitrile 884658-94-0P,
 [2-Fluoro-4-(2-methylthiazol-4-ylmethoxy)phenyl][2-(2-methylpyrrolidin-1-ylmethyl)pyrrolidin-1-yl]methanone 884658-95-1P,
 4-[[3-Fluoro-4-[2-(2-methylpyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl]phenoxy]methyl]thiophene-2-carbonitrile 884658-96-2P,

[2-Fluoro-4-((1,2,4)oxadiazol-3-ylmethoxy)phenyl][2-(2-methylpyrrolidin-1-ylmethyl)pyrrolidin-1-yl]methanone 884658-97-3P,
 [2-Fluoro-4-(5-methylisoxazol-3-ylmethoxy)phenyl][2-(2-methylpyrrolidin-1-ylmethyl)pyrrolidin-1-yl]methanone 884658-98-4P,
 [2-Fluoro-4-(5-trifluoromethylfuran-2-ylmethoxy)phenyl][2-(2-methylpyrrolidin-1-ylmethyl)pyrrolidin-1-yl]methanone 884658-99-5P,
 , 5-[[3-Fluoro-4-[(2-(2-methylpyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl]phenoxy]methyl]thiophene-3-carbonitrile 884659-00-1P
 884659-33-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of benzoylpyrrolidines as histamine

H3 receptor inhibitors)

RN 884658-56-4 CAPLUS

CN 2-Thiophenecarbonitrile, 5-[[4-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 884658-57-5 CAPLUS

CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-(4-thiazolylmethoxy)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 884658-59-7 CAPLUS

CN Methanone, [2-fluoro-4-(4-thiazolylmethoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 884658-61-1 CAPLUS

CN Methanone, [2-fluoro-4-(2-furanylmethoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 884658-62-2 CAPLUS

CN 2-Thiophenecarbonitrile, 5-[[3-fluoro-4-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 884658-63-3 CAPLUS

CN Methanone, [2,6-difluoro-4-(4-thiazolylmethoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 884658-64-4 CAPLUS

CN Methanone, [2-fluoro-4-(4-thiazolylmethoxy)phenyl][(2S)-2-[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 884658-65-5 CAPLUS

CN Methanone, [2,6-difluoro-4-(4-thiazolylmethoxy)phenyl][(2S)-2-[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 884658-66-6 CAPLUS

CN Methanone, [2-fluoro-4-[(2-methyl-4-thiazolyl)methoxy]phenyl][(2S)-2-(1-pyrrolidinyl)methyl]-1-pyrrolidinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 884658-67-7 CAPLUS

CN Methanone, [2-fluoro-4-(3-thienylmethoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 884658-68-8 CAPLUS

CN Methanone, [2-fluoro-4-(3-thienylmethoxy)phenyl][(2S)-2-[(2R)-2-methyl-1-pyrrolidinylmethyl]-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 884658-69-9 CAPLUS

CN Methanone, [2-fluoro-4-(2-thienylmethoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 884658-70-2 CAPLUS

CN Methanone, [2-fluoro-4-(2-thienylmethoxy)phenyl] [(2S)-2-[[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 884658-71-3 CAPLUS

CN 2-Thiophenecarbonitrile, 5-[[3-fluoro-4-[[(2S)-2-[[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]carbonyl]phenoxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 884658-72-4 CAPLUS

CN Methanone, [2-fluoro-4-[(2-methyl-4-thiazolyl)methoxy]phenyl] [(2S)-2-[[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 884658-73-5 CAPLUS

CN 2-Thiophenecarbonitrile, 4-[[3-fluoro-4-[[[(2S)-2-[[[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]carbonyl]phenoxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 884658-74-6 CAPLUS

CN Methanone, [2-fluoro-4-(1,2,4-oxadiazol-3-ylmethoxy)phenyl] [(2S)-2-[[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 884658-75-7 CAPLUS

CN Methanone, [2-fluoro-4-(1,2,4-oxadiazol-3-ylmethoxy)phenyl][[(2S)-2-[[[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CRN 884658-74-6
CMF C20 H25 F N4 O3

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 884658-76-8 CAPLUS
CN Methanone, [2-fluoro-4-[(5-methyl-3-isoxazolyl)methoxy]phenyl][(2S)-2-[[[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 884658-77-9 CAPLUS
CN Methanone, [2-fluoro-4-[(5-methyl-3-isoxazolyl)methoxy]phenyl][(2S)-2-[[[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 884658-76-8
CMF C22 H28 F N3 O3

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 884658-78-0 CAPLUS
CN Methanone, [2-fluoro-4-[[5-(trifluoromethyl)-2-furanyl]methoxy]phenyl][[(2S)-2-[[[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 884658-79-1 CAPLUS
CN Methanone, [2-fluoro-4-[[5-(trifluoromethyl)-2-furanyl]methoxy]phenyl][[(2S)-2-[[[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 884658-78-0

Absolute stereochemistry.




CRN 76-05-1
CMF C2 H F3 O2




RN 884658-80-4 CAPLUS
CN 3-Thiophenecarbonitrile, 5-[[3-fluoro-4-[(2S)-2-[[[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]carbonyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN	884658-81-5	CAPLUS
CN	2-Thiophenecarbonitrile, 5-[[4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]- (CA INDEX NAME)	




RN 884658-82-6 CAPLUS

CN Methanone, [2-fluoro-4-(4-thiazolylmethoxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 884658-83-7 CAPLUS

CN Methanone, [4-(2-furanylmethoxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 884658-84-8 CAPLUS

CN 2-Thiophenecarbonitrile, 5-[[3-fluoro-4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]- (CA INDEX NAME)




RN 884658-85-9 CAPLUS

CN Methanone, [2,6-difluoro-4-(4-thiazolylmethoxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 884658-86-0 CAPLUS

CN Methanone, [2-fluoro-4-(4-thiazolylmethoxy)phenyl][2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)




RN 884658-87-1 CAPLUS

CN Methanone, [2,6-difluoro-4-(4-thiazolylmethoxy)phenyl][2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)




RN 884658-88-2 CAPLUS

CN Methanone, [2-fluoro-4-[(2-methyl-4-thiazolyl)methoxy]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 884658-89-3 CAPLUS

CN Methanone, [2-fluoro-4-(3-thienylmethoxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 884658-90-6 CAPLUS

CN Methanone, [2-fluoro-4-(3-thienylmethoxy)phenyl][2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)




RN 884658-91-7 CAPLUS

CN Methanone, [2-fluoro-4-(2-thienylmethoxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 884658-92-8 CAPLUS

CN Methanone, [2-fluoro-4-(2-thienylmethoxy)phenyl][2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)




RN 884658-93-9 CAPLUS

CN 2-Thiophenecarbonitrile, 5-[[[3-fluoro-4-[[[2-(methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]carbonyl]phenoxy]methyl]- (CA INDEX NAME)




RN 884658-94-0 CAPLUS

CN Methanone, [2-fluoro-4-[(2-methyl-4-thiazolyl)methoxy]phenyl][2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)




RN 884658-95-1 CAPLUS

CN 2-Thiophenecarbonitrile, 4-[[[3-fluoro-4-[[2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]carbonyl]phenoxy]methyl]- (CA INDEX NAME)




RN 884658-96-2 CAPLUS

CN Methanone, [2-fluoro-4-(1,2,4-oxadiazol-3-ylmethoxy)phenyl][2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)




RN 884658-97-3 CAPLUS

CN Methanone, [2-fluoro-4-[(5-methyl-3-isoxazolyl)methoxy]phenyl][2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)




RN 884658-98-4 CAPLUS

CN Methanone, [2-fluoro-4-[[5-(trifluoromethyl)-2-furanyl]methoxy]phenyl][2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)



RN 884658-99-5 CAPLUS


CN 3-Thiophenecarbonitrile, 5-[[[3-fluoro-4-[[2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]carbonyl]phenoxy]methyl]- (CA INDEX NAME)



RN 884659-00-1 CAPLUS


CN Methanone, [4-(2-furanylmethoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 884659-33-0 CAPLUS

CN Methanone, [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-(4-thiazolylmethoxy)phenyl]- (CA INDEX NAME)




IT 871489-49-5P 871489-50-8P 871489-59-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of benzoylpyrrolidines as histamine H3 receptor inhibitors)

RN 871489-49-5 CAPLUS


CN Methanone, (4-hydroxyphenyl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 871489-50-8 CAPLUS
CN Methanone, (2-fluoro-4-hydroxyphenyl) [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 871489-59-7 CAPLUS
CN Methanone, (2-fluoro-4-hydroxyphenyl) [(2S)-2-[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:193420 CAPLUS
DOCUMENT NUMBER: 144:274129
TITLE: Preparation of 1-(hetero)aroyl-2-(pyrrolidin-1-ylmethyl)pyrrolidine histamine H3 receptor agents and therapeutic uses
INVENTOR(S): Finley, Don Richard; Finn, Terry Patrick; Hipskind, Philip Arthur; Hornback, William Joseph; Jesudason, Cynthia Darshini; Takakuwa, Takako

PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 123 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006023462	A1	20060302	WO 2005-US29032	20050815
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2005277518	A1	20060302	AU 2005-277518	20050815
CA 2577061	A1	20060302	CA 2005-2577061	20050815
EP 1784400	A1	20070516	EP 2005-789881	20050815
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 101006082	A	20070725	CN 2005-80028163	20050815
JP 2008510808	T	20080410	JP 2007-529947	20050815
BR 2005014553	A	20080617	BR 2005-14553	20050815
IN 2007KN00388	A	20070706	IN 2007-KN388	20070205
MX 200702274	A	20070507	MX 2007-2274	20070223
PRIORITY APPLN. INFO.:			US 2004-603628P	P 20040823
			WO 2005-US29032	W 20050815
OTHER SOURCE(S):			CASREACT 144:274129; MARPAT 144:274129	
GI				




AB The present invention provides 1-(hetero)aryl-2-(pyrrolidin-1-

ylmethyl)pyrrolidines (shown as I; variables defined below; e.g. (S)-[4-[4-(pyridin-3-yl)thiazol-2-yl]phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl]methanone dihydrochloride (free base shown as II)) or a pharmaceutically acceptable salt thereof, having histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compds. In another embodiment, the invention discloses pharmaceutical compns. comprising compds. I as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.


Although the methods of preparation are not claimed, preps. and/or characterization data for 57 examples of I are included. For example, II was prepared by converting sodium 4-[4-(pyridin-3-yl)thiazol-2-yl]benzoate to the acid chloride and then condensing it with (S)-(+)-1-[(2-pyrrolidinyl)methyl]pyrrolidine in the presence of pyridine. For I: X = C (substituted with H or the optional substituents indicated herein), or N; R1 = -HET ((un)substituted on C, independently, 1-3 times with R2, and optionally once substituted on N with R3), or benzo-fused heterocycle ((un)substituted on C, independently, 1-3 times with R2, and optionally once substituted on N with R3); R2 = at each occurrence -H, -halogen, -(C1-C7) alkyl ((un)substituted with 1-3 halogens), -CN, -C(O)R7, -C(O)OR7, et al. R3 = at each occurrence -H, -(C1-C7) alkyl ((un)substituted with 1-3 halogens), -SO2R7, -C(O)R7, -C(O)NR7R8, or -C(O)OR7; R4 and R5 = -H, -OH, -halogen, -(C1-C3)alkyl ((un)substituted with 1-3 halogens), or -OR9, provided that when X is N, then R4 and R5 are not attached to X; R6 = -H, -halo, -(C1-C3) alkyl ((un)substituted with 1-3 halogens), -NH2, -NR7R8, -OH, or -OR7; R7 and R8 = -H, -Ph, -(C1-C7) alkyl ((un)substituted with 1-3 halogens); or R7 and R8 combine with the atom to which they are attached to form a 4 to 7 membered ring; R9 is -H, -halo, -(C1-C3) alkyl ((un)substituted with 1-3 halogens), or -OR7. All compds. set forth in the examples exhibit affinity for the H3 receptor >1 μ M in the H3R binding assay; e.g. $K_i = 3.1$ nM for II·2HCl.

II 867256-60-8, (4-Bromo-2-fluorophenyl)[(S)-2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl]methanone 877675-35-9,
4-[[2-[(Pyrrolidin-1-yl)methyl]pyrrolidin-1-yl]carbonyl]phenyl bromide
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 1-(hetero)aryl-2-(pyrrolidin-1-ylmethyl)pyrrolidine
histamine H3 receptor agents and therapeutic uses)
RN 867256-60-8 CAPLUS
CN Methanone, (4-bromo-2-fluorophenyl)[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 877675-35-9 CAPLUS
CN Methanone, (4-bromo-2-fluorophenyl)[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1331244 CAPLUS

DOCUMENT NUMBER: 144:51445

TITLE: Preparation of 2-(pyrrolidin-1-ylmethyl)pyrrolidine derivatives as histamine H3 receptor antagonists

INVENTOR(S): Beavers, Lisa Selsam; Gadski, Robert Alan; Jesudason, Cynthia Darshini; Pickard, Richard Todd; Stevens, Freddie Craig

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005121080	A1	20051222	WO 2005-US18249	20050524
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005252178	A1	20051222	AU 2005-252178	20050524
CA 2567513	A1	20051222	CA 2005-2567513	20050524
EP 1756051	A1	20070228	EP 2005-754884	20050524
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 1956952	A	20070502	CN 2005-80016836	20050524
BR 2005011642	A	20080102	BR 2005-11642	20050524
JP 2008501687	T	20080124	JP 2007-515269	20050524
IN 2006KN03536	A	20070615	IN 2006-KN3536	20061127
MX 2006PA13951	A	20070315	MX 2006-PA13951	20061130
PRIORITY APPLN. INFO.:			US 2004-576421P	P 20040602
			WO 2005-US18249	W 20050524

OTHER SOURCE(S):
GI

CASREACT 144:51445; MARPAT 144:51445



I



II

AB The title compds. I [wherein Ar = (un)substituted (hetero)aryl; R1 and R2 = independently H, OH, halo, CF₃, etc.; R3 = H, halo, CF₃, NH₂, etc.] or enantiomers or pharmaceutically acceptable salts thereof were prepared as histamine-H3 receptor antagonists. For example, the compound II•CF₃CO₂H was prepared II•CF₃CO₂H showed antagonistic activity to [35S]GTP γ[S] with K_i of 4.1 nM. I are useful for the treatment of obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases (no data).

IT 871488-55-0P 871488-71-0P 871488-74-3P

871489-38-2P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of (pyrrolidinylmethyl)pyrrolidine derivs. as histamine H3 receptor antagonists)

RN 871488-55-0 CAPLUS

CN Benzoic acid, 4-[[4-[[[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-71-0 CAPLUS

CN Methanone, [4-(2-pyridinylmethoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-74-3 CAPLUS


CN Methanone, [2-fluoro-4-(2-pyridinylmethoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 871489-38-2 CAPLUS

CN Benzoic acid, 4-[[4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]-, lithium salt (1:1) (CA INDEX NAME)



IT 871487-72-8P 871487-75-1P 871487-78-4P
 871487-81-9P 871487-84-2P 871487-87-5P
 871487-90-0P 871487-93-3P 871487-96-6P
 871487-99-9P 871488-02-7P 871488-07-2P
 871488-11-8P 871488-15-2P 871488-19-6P
 871488-23-2P 871488-27-6P 871488-30-1P
 871488-33-4P 871488-35-6P 871488-37-8P
 871488-40-3P 871488-42-5P 871488-44-7P
 871488-47-0P 871488-50-5P 871488-53-8P
 871488-57-2P 871488-59-4P 871488-61-8P
 871488-62-9P 871488-63-0P 871488-64-1P
 871488-65-2P 871488-66-3P 871488-67-4P
 871488-68-5P 871488-69-6P 871488-70-9P
 871488-72-1P 871488-73-2P 871488-75-4P
 871488-76-5P 871488-77-6P 871488-78-7P
 871488-79-8P 871488-80-1P 871488-81-2P
 871488-82-3P 871488-83-4P 871488-84-5P
 871488-85-6P 871488-87-8P 871488-89-0P
 871488-91-4P 871488-92-5P 871488-93-6P
 871488-94-7P 871488-95-8P 871488-96-9P
 871488-97-0P 871488-98-1P 871488-99-2P
 871489-00-8P 871489-01-9P 871489-02-0P
 871489-03-1P 871489-04-2P 871489-05-3P
 871489-06-4P 871489-07-5P 871489-08-6P
 871489-09-7P 871489-10-0P 871489-11-1P
 871489-12-2P 871489-13-3P 871489-14-4P
 871489-15-5P 871489-16-6P 871489-17-7P
 871489-18-8P 871489-19-9P 871489-20-2P
 871489-21-3P 871489-22-4P 871489-23-5P
 871489-24-6P 871489-25-7P 871489-26-8P
 871489-27-9P 871489-28-0P 871489-29-1P
 871489-30-4P 871489-31-5P 871489-32-6P
 871489-33-7P 871489-34-8P 871489-35-9P
 871489-36-0P 871489-37-1P 871489-39-3P
 871489-40-6P 871489-41-7P 871489-43-9P
 871489-44-0P 871489-45-1P 871489-46-2P
 871489-47-3P 871489-48-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


(Uses)

(drug candidate; preparation of (pyrrolidinylmethyl)pyrrolidine derivs. as histamine H3 receptor antagonists)

RN 871487-72-8 CAPLUS

CN Methanone, [4-(phenylmethoxy)phenyl] [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 871487-75-1 CAPLUS


CN Benzonitrile, 3-[[4-[[[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 871487-74-0

CMF C24 H27 N3 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 871487-78-4 CAPLUS


CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-[[3-(trifluoromethoxy)phenyl]methoxy]phenyl]-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 871487-77-3

CMF C24 H27 F3 N2 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 871487-81-9 CAPLUS


CN Methanone, [4-[(3-methoxyphenyl)methoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 871487-80-8

CMF C24 H30 N2 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 871487-84-2 CAPLUS


CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 871487-83-1

CMF C24 H27 F3 N2 O2

Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 871487-87-5 CAPLUS
 CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)
 CM 1
 CRN 871487-86-4
 CMF C24 H27 F3 N2 O2

Absolute stereochemistry.




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 871487-90-0 CAPLUS
 CN Methanone, [4-[(4-methylphenyl)methoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)
 CM 1
 CRN 871487-89-7
 CMF C24 H30 N2 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 871487-93-3 CAPLUS


CN Methanone, [4-[(3-methylphenyl)methoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 871487-92-2

CMF C24 H30 N2 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 871487-96-6 CAPLUS
 CN Benzonitrile, 4-[[4-[[{(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 871487-95-5
 CMF C24 H27 N3 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 871487-99-9 CAPLUS
 CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-[[4-(trifluoromethoxy)phenyl]methoxy]phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 871487-98-8
 CMF C24 H27 F3 N2 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 871488-02-7 CAPLUS


CN Methanone, [4-[(3-fluorophenyl)methoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 871488-01-6

CMF C23 H27 F N2 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 871488-07-2 CAPLUS
 CN Methanone, [4-[(4-fluorophenyl)methoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 871488-06-1
 CMF C23 H27 F N2 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 871488-11-8 CAPLUS
 CN Methanone, [4-[(2-methylphenyl)methoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 871488-10-7
 CMF C24 H30 N2 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 871488-15-2 CAPLUS


CN Methanone, [4-[(2,6-difluorophenyl)methoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 871488-14-1

CMF C23 H26 F2 N2 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 871488-19-6 CAPLUS
 CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-[[2-(trifluoromethyl)phenyl]methoxy]phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 871488-18-5

CMF C24 H27 F3 N2 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 871488-23-2 CAPLUS
 CN Methanone, [4-[[2-[(phenylsulfonyl)methyl]phenyl]methoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 871488-22-1

CMF C30 H34 N2 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 871488-27-6 CAPLUS
CN Pyrrolidine, 1-[4-[(4-benzoylphenyl)methoxy]benzoyl]-2-(1-pyrrolidinylmethyl)-, (2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 871488-26-5
CMF C30 H32 N2 O3

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 871488-30-1 CAPLUS

CN Methanone, [4-(3-pyridinylmethoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-33-4 CAPLUS

CN Methanone, [4-(4-pyridinylmethoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-35-6 CAPLUS

CN Methanone, [4-[[4-(methylsulfonyl)phenyl]methoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-37-8 CAPLUS

CN Benamide, N,N-dimethyl-4-[[4-[[[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-40-3 CAPLUS

CN Benamide, N,N-dimethyl-3-[[4-[[[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 871488-42-5 CAPLUS

CN Benamide, N-methyl-4-[[4-[[[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]- (CA INDEX NAME)

pyrrolidinyl]carbonyl]phenoxy)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-44-7 CAPLUS

CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-[[6-(trifluoromethyl)-3-pyridinyl]methoxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-47-0 CAPLUS

CN Methanone, [4-[[6-chloro-3-pyridinyl]methoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 871488-50-5 CAPLUS
 CN Methanone, [4-[(4-methoxyphenyl)methoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 871488-49-2
 CMF C24 H30 N2 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 871488-53-8 CAPLUS
 CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-[[2-(trifluoromethoxy)phenyl]methoxy]phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 871488-52-7
 CMF C24 H27 F3 N2 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 871488-57-2 CAPLUS

CN Methanone, [4-[[4-(1-pyrrolidinylcarbonyl)phenyl]methoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-59-4 CAPLUS

CN Methanone, [4-[[4-(1-azetidylcarbonyl)phenyl]methoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-61-8 CAPLUS

CN Methanone, [4-[[4-(1-piperidinylcarbonyl)phenyl]methoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-62-9 CAPLUS

CN Methanone, [2-fluoro-4-[[4-(methanesulfonyl)phenyl]methoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-63-0 CAPLUS

CN Benzamide, 4-[[3-fluoro-4-[[{(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]-N,N-dimethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-64-1 CAPLUS

CN Methanone, [2-fluoro-4-(4-pyridinylmethoxy)phenyl][{(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-65-2 CAPLUS

CN Methanone, [4-(6-chloro-3-pyridinylmethoxy)-2-fluorophenyl][{(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-66-3 CAPLUS

CN Methanone, [2-fluoro-4-[(4-fluorophenyl)methoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-67-4 CAPLUS

CN Methanone, [3-fluoro-4-[[4-(methylsulfonyl)phenyl]methoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-68-5 CAPLUS

CN Benzamide, 4-[[[2-fluoro-4-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-69-6 CAPLUS

CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-[[4-((trifluoromethyl)thio)phenyl]methoxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-70-9 CAPLUS

CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-[[4-(trifluoromethyl)sulfonyl]phenyl]methoxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-72-1 CAPLUS

CN Methanone, [4-(2-pyridinylmethoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 871488-73-2 CAPLUS

CN Methanone, [4-[(4-fluorophenyl)methoxy]phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 871488-75-4 CAPLUS

CN Methanone, [2-fluoro-4-(2-pyridinylmethoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 871488-76-5 CAPLUS

CN Methanone, [2,6-difluoro-4-(2-pyridinylmethoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-77-6 CAPLUS

CN Methanone, [2-fluoro-4-(2-pyridinylmethoxy)phenyl][(2S)-2-[(2R)-2-methyl-1-pyrrolidinylmethyl]-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 871488-78-7 CAPLUS

CN Methanone, [4-(2-pyrazinylmethoxy)phenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-

pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-79-8 CAPLUS

CN Benzoic acid, 4-[[4-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]-, lithium salt (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● Li

RN 871488-80-1 CAPLUS

CN Methanone, [2,6-difluoro-4-(2-pyridinylmethoxy)phenyl][(2S)-2-[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-81-2 CAPLUS

CN Methanone, [(2S)-2-[(2R)-2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl][4-(2-pyridinylmethoxy)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-82-3 CAPLUS

CN Methanone, [4-(2-pyridinylmethoxy)phenyl][(2R)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-83-4 CAPLUS

CN Methanone, [2-fluoro-4-[(6-methyl-2-pyridinyl)methoxy]phenyl][(2S)-2-[(2R)-2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-84-5 CAPLUS

CN Methanone, [4-[(6-methyl-2-pyridinyl)methoxy]phenyl][(2S)-2-[[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871488-85-6 CAPLUS

CN Methanone, [2-fluoro-4-[[4-(methylsulfonyl)phenyl]methoxy]phenyl][(2S)-2-[[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 871488-87-8 CAPLUS
 CN Methanone, [2-fluoro-4-[(4-fluorophenyl)methoxy]phenyl][(2S)-2-[[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 871488-86-7
 CMF C24 H28 F2 N2 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 871488-89-0 CAPLUS
 CN Methanone, [2-fluoro-4-[[2-[(phenylsulfonyl)methyl]phenyl]methoxy]phenyl][(2S)-2-[[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 871488-88-9
 CMF C31 H35 F N2 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 871488-91-4 CAPLUS


CN Methanone, [2-fluoro-4-[(6-methoxy-3-pyridinyl)methoxy]phenyl][(2S)-2-
 [(2R)-2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]-,
 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 871488-90-3

CMF C24 H30 F N3 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 871488-92-5 CAPLUS


CN Methanone, [4-[2-fluoro-4-[(trifluoromethyl)sulfonyl]phenyl]methoxy]phenyl [(2S)-2-[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 871488-93-6 CAPLUS

CN Methanone, [4-(phenylmethoxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871488-94-7 CAPLUS

CN Benzonitrile, 3-[[4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]- (CA INDEX NAME)




RN 871488-95-8 CAPLUS

CN Methanone, [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-[[3-(trifluoromethoxy)phenyl]methoxy]phenyl]- (CA INDEX NAME)




RN 871488-96-9 CAPLUS

CN Methanone, [4-[(3-methoxyphenyl)methoxy]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871488-97-0 CAPLUS

CN Methanone, [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]- (CA INDEX NAME)




RN 871488-98-1 CAPLUS

CN Methanone, [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]- (CA INDEX NAME)




RN 871488-99-2 CAPLUS

CN Methanone, [4-[(4-methylphenyl)methoxy]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-00-8 CAPLUS


CN Methanone, [4-[(3-methylphenyl)methoxy]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)



RN 871489-01-9 CAPLUS
 CN Benzonitrile, 4-[[4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]- (CA INDEX NAME)




RN 871489-02-0 CAPLUS
 CN Methanone, [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-[[4-(trifluoromethoxy)phenyl]methoxy]phenyl]- (CA INDEX NAME)




RN 871489-03-1 CAPLUS

CN Methanone, [4-[(3-fluorophenyl)methoxy]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-04-2 CAPLUS

CN Methanone, [4-[(4-fluorophenyl)methoxy]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-05-3 CAPLUS

CN Methanone, [4-[(2-methylphenyl)methoxy]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-06-4 CAPLUS

CN Methanone, [4-[(2,6-difluorophenyl)methoxy]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-07-5 CAPLUS

CN Methanone, [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-[[2-(trifluoromethyl)phenyl]methoxy]phenyl]- (CA INDEX NAME)




RN 871489-08-6 CAPLUS


CN Methanone, [4-[[2-[(phenylsulfonyl)methyl]phenyl]methoxy]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)



RN 871489-09-7 CAPLUS
 CN Pyrrolidine, 1-[4-[(4-benzoylphenyl)methoxy]benzoyl]-2-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 871489-10-0 CAPLUS
 CN Methanone, [4-(3-pyridinylmethoxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-11-1 CAPLUS

CN Methanone, [4-(4-pyridinylmethoxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-12-2 CAPLUS

CN Methanone, [4-[[4-(4-methylsulfonylphenyl)methoxy]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-13-3 CAPLUS

CN Benzamide, N,N-dimethyl-4-[[4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]- (CA INDEX NAME)




RN 871489-14-4 CAPLUS

CN Benzamide, N,N-dimethyl-3-[[4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]- (CA INDEX NAME)




RN 871489-15-5 CAPLUS

CN Benzamide, N-methyl-4-[[4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]- (CA INDEX NAME)




RN 871489-16-6 CAPLUS

CN Methanone, [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-[[6-(trifluoromethyl)-3-pyridinyl]methoxy]phenyl]- (CA INDEX NAME)




RN 871489-17-7 CAPLUS

CN Methanone, [4-[(6-chloro-3-pyridinyl)methoxy]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-18-8 CAPLUS

CN Methanone, [4-[(4-methoxyphenyl)methoxy]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-19-9 CAPLUS

CN Methanone, [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-[[2-(trifluoromethoxy)phenyl]methoxy]phenyl]- (CA INDEX NAME)




RN 871489-20-2 CAPLUS

CN Benzoic acid, 4-[[[4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]-, methyl ester (CA INDEX NAME)




RN 871489-21-3 CAPLUS

CN Methanone, [4-[[4-(1-pyrrolidinylcarbonyl)phenyl]methoxy]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)



RN 871489-22-4 CAPLUS


CN Methanone, [4-[[4-(1-azetidiny carbonyl)phenyl]methoxy]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-23-5 CAPLUS

CN Methanone, [4-[[4-(1-piperidinylcarbonyl)phenyl]methoxy]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


PAGE 1-A






RN 871489-24-6 CAPLUS

CN Methanone, [2-fluoro-4-[[4-(methylsulfonyl)phenyl]methoxy]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-25-7 CAPLUS

CN Benzamide, 4-[[3-fluoro-4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]-N,N-dimethyl- (CA INDEX NAME)




RN 871489-26-8 CAPLUS

CN Methanone, [2-fluoro-4-(4-pyridinylmethoxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-27-9 CAPLUS

CN Methanone, [4-[(6-chloro-3-pyridinyl)methoxy]-2-fluorophenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-28-0 CAPLUS

CN Methanone, [2-fluoro-4-[(4-fluorophenyl)methoxy]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-29-1 CAPLUS


CN Methanone, [3-fluoro-4-[[4-(methylsulfonyl)phenyl]methoxy]phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)



RN 871489-30-4 CAPLUS
 CN Benzanide, 4-[[2-fluoro-4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]-N,N-dimethyl- (CA INDEX NAME)




RN 871489-31-5 CAPLUS
 CN Methanone, [2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][4-[[4-((trifluoromethyl)thio)phenyl]methoxy]phenyl]- (CA INDEX NAME)




RN 871489-32-6 CAPLUS

CN Methanone, [2-((1-pyrrolidinylmethyl)-1-pyrrolidinyl)][4-[[4-(trifluoromethyl)sulfonyl]phenyl]methoxy]phenyl]- (CA INDEX NAME)




RN 871489-33-7 CAPLUS

CN Methanone, [4-(2-pyridinylmethoxy)phenyl][2-((1-pyrrolidinylmethyl)-1-pyrrolidinyl)- (CA INDEX NAME)]




RN 871489-34-8 CAPLUS

CN Methanone, [2-fluoro-4-(2-pyridinylmethoxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-35-9 CAPLUS

CN Methanone, [2,6-difluoro-4-(2-pyridinylmethoxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-36-0 CAPLUS

CN Methanone, [2-fluoro-4-(2-pyridinylmethoxy)phenyl][2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-37-1 CAPLUS

CN Methanone, [4-(2-pyrazinylmethoxy)phenyl][2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-39-3 CAPLUS

CN Methanone, [2,6-difluoro-4-(2-pyridinylmethoxy)phenyl][2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-40-6 CAPLUS

CN Methanone, [2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl][4-(2-pyridinylmethoxy)phenyl]- (CA INDEX NAME)




RN 871489-41-7 CAPLUS

CN Methanone, [2-fluoro-4-[(6-methyl-2-pyridinyl)methoxy]phenyl][2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-43-9 CAPLUS

CN Methanone, [4-[(6-methyl-2-pyridinyl)methoxy]phenyl][2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-44-0 CAPLUS

CN Methanone, [2-fluoro-4-[[4-(methylsulfonyl)phenyl]methoxy]phenyl][2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-45-1 CAPLUS

CN Methanone, [2-fluoro-4-[[4-(4-fluorophenyl)methoxy]phenyl][2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-46-2 CAPLUS

CN Methanone, [2-fluoro-4-[[2-[(phenylsulfonyl)methyl]phenyl]methoxy]phenyl][2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)




RN 871489-47-3 CAPLUS

CN Methanone, [2-fluoro-4-[(6-methoxy-3-pyridinyl)methoxy]phenyl][2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)



RN 871489-48-4 CAPLUS

CN Methanone, [4-[[2-fluoro-4-[(trifluoromethyl)sulfonyl]phenyl]methoxy]phenyl][2-[(2-methyl-1-pyrrolidinyl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)



IT 464900-48-9P 871489-49-5P 871489-50-8P
871489-59-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of (pyrrolidinylmethyl)pyrrolidine derivs. as histamine H3 receptor antagonists)

RN 464900-48-9 CAPLUS

CN Methanone, (3-fluoro-4-hydroxyphenyl)[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 871489-49-5 CAPLUS

CN Methanone, (4-hydroxyphenyl) [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 871489-50-8 CAPLUS

CN Methanone, (2-fluoro-4-hydroxyphenyl) [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 871489-59-7 CAPLUS

CN Methanone, (2-fluoro-4-hydroxyphenyl) [(2S)-2-[(2R)-2-methyl-1-pyrrolidinyl]methyl]-1-pyrrolidinyl]-
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

39.82 218.85

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY SESSION

-4.80 -4.80

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 17:27:09 ON 07 AUG 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAPEZ1617

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 NOV 21 CAS patent coverage to include exemplified prophetic
substances identified in English-, French-, German-,
and Japanese-language basic patents from 2004-present
NEWS 3 NOV 26 MARPAT enhanced with FSORT command
NEWS 4 NOV 26 CHEMSAFE now available on STN Easy
NEWS 5 NOV 26 Two new SET commands increase convenience of STN
searching
NEWS 6 DEC 01 ChemPort single article sales feature unavailable
NEWS 7 DEC 12 GBFULL now offers single source for full-text
coverage of complete UK patent families
NEWS 8 DEC 17 Fifty-one pharmaceutical ingredients added to PS
NEWS 9 JAN 06 The retention policy for unread STNmail messages
will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
Classification Data
NEWS 11 FEB 02 Simultaneous left and right truncation (SLART) added
for CERAB, COMPUAB, ELCOM, and SOLIDSTATEM
NEWS 12 FEB 02 GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 13 FEB 06 Patent sequence location (PSL) data added to USGENE

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 14:11:22 ON 06 FEB 2009

=> fil reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 14:11:32 ON 06 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 4 FEB 2009 HIGHEST RN 1100909-82-7
DICTIONARY FILE UPDATES: 4 FEB 2009 HIGHEST RN 1100909-82-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10599488 generic.str



```
chain nodes :  
7 13 19  
ring nodes :  
1 2 3 4 5 6 8 9 10 11 12 14 15 16 17 18 20 21 22 23 24 25  
chain bonds :  
5-7 7-8 9-13 13-14 15-19  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-12 9-10 10-11 11-12 14-15 14-18 15-16  
16-17 17-18 20-21 20-25 21-22 22-23 23-24 24-25  
exact/norm bonds :  
7-8 8-9 8-12 9-10 9-13 10-11 11-12 13-14 14-15 14-18 15-16 16-17 17-18  
exact bonds :  
5-7 15-19  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 20-21 20-25 21-22 22-23 23-24 24-25
```

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 27:Atom

Generic attributes :

13:

Type of chain : Linear

Saturation : Saturated


Number of Carbon Atoms : less than 7

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 14:11:55 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 29119 TO ITERATE

6.9% PROCESSED 2000 ITERATIONS

0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 572171 TO 592589

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss ful
FULL SEARCH INITIATED 14:12:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 581875 TO ITERATE

100.0% PROCESSED 581875 ITERATIONS 28 ANSWERS
SEARCH TIME: 00.00.09

L3 28 SEA SSS FUL L1

=> fil cap
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 185.88 186.10

FILE 'CAPLUS' ENTERED AT 14:12:13 ON 06 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Feb 2009 VOL 150 ISS 7
FILE LAST UPDATED: 5 Feb 2009 (20090205/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 1 L3

=> d l4

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:1123882 CAPLUS
DN 143:405796
TI Preparation of aroyl-substituted pyrrolidines as histamine H3 receptor ligands
IN Beavers, Lisa Selsam; Finley, Don Richard; Finn, Terry Patrick; Gadske, Robert Alan; Hipkind, Philip Arthur; Hornback, William Joseph; Jesudason, Cynthia Darshini; Pickard, Richard Todd; Takakuwa, Takako; Vaught, Grant Mathews
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 179 pp.
CODEN: PIXXD2
DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005097740	A1	20051020	WO 2005-US10240	20050325
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005230881	A1	20051020	AU 2005-230881	20050325
	CA 2561628	A1	20051020	CA 2005-2561628	20050325
	EP 1735278	A1	20061227	EP 2005-730691	20050325
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 1960969	A	20070509	CN 2005-80017146	20050325
	BR 2005009298	A	20070918	BR 2005-9298	20050325
	JP 2007530698	T	20071101	JP 2007-506412	20050325
	MX 2006011167	A	20070125	MX 2006-11167	20060928
	US 20070208024	A1	20070906	US 2006-599488	20060929
	IN 2006KN02868	A	20070608	IN 2006-KN2868	20061005
FRAI	US 2004-558542P	P	20040401		
	US 2004-617101P	P	20041008		
	WO 2005-US10240	W	20050325		
OS	CASREACT 143:405796; MARPAT 143:405796				
RE.CNT 3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD				
	ALL CITATIONS AVAILABLE IN THE RE FORMAT				

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

2.25

188.35

STN INTERNATIONAL LOGOFF AT 14:13:12 ON 06 FEB 2009